Gilles Montalescot

Gilles Montalescot's AcademicInfluence.com Rankings

Gilles Montalescot

Medical

#1380

World Rank

#1712

Historical Rank

Cardiology

#104

World Rank

#106

Historical Rank

medical Degrees

Gilles Montalescot

Philosophy

#4423

World Rank

#6928

Historical Rank

Logic

#1875

World Rank

#2735

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Gilles Montalescot's Degrees

PhD Cardiology Université Paris Cité
Doctorate Medicine Université Paris Cité

Why Is Gilles Montalescot Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Gilles Montalescot's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Prasugrel versus clopidogrel in patients with acute coronary syndromes. (2007) (6103)
ESC / EACTS Guidelines on myocardial revascularization (2012) (5643)
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. (2013) (3723)
2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous (2014) (3302)
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. (2006) (2183)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. (2018) (1802)
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. (2005) (1559)
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. (2010) (1127)
Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial (2009) (1082)
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. (2010) (1061)
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study (2009) (980)
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. (2001) (917)
[2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018) (913)
Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial (2007) (905)
Bedside monitoring to adjust antiplatelet therapy for coronary stenting. (2012) (840)
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial (2010) (808)
Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. (2005) (735)
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. (2012) (718)
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. (2007) (625)
PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock (2017) (614)
Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). (2005) (596)
Intravenous platelet blockade with cangrelor during PCI. (2009) (590)
Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). (2004) (586)
Platelet inhibition with cangrelor in patients undergoing PCI. (2009) (571)
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. (2006) (564)
Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. (2013) (541)
Transfer for Primary Angioplasty Versus Immediate Thrombolysis in Acute Myocardial Infarction: A Meta-Analysis (2003) (491)
Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial (2009) (486)
Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. (2004) (476)
Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. (2000) (473)
Evacetrapib and Cardiovascular Outcomes in High‐Risk Vascular Disease (2017) (462)
Aspirin dose for the prevention of cardiovascular disease: a systematic review. (2007) (457)
Facilitated PCI in patients with ST-elevation myocardial infarction. (2008) (456)
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. (2004) (419)
Early versus delayed, provisional eptifibatide in acute coronary syndromes. (2009) (406)
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. (2012) (397)
Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. (2010) (391)
Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) (2003) (391)
Impact of Prior Use or Recent Withdrawal of Oral Antiplatelet Agents on Acute Coronary Syndromes (2004) (388)
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. (2006) (352)
Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. (2015) (342)
Altered Fibrin Architecture Is Associated With Hypofibrinolysis and Premature Coronary Atherothrombosis (2006) (341)
Composition of coronary thrombus in acute myocardial infarction. (2011) (336)
Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). (2006) (332)
STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). (2006) (325)
Platelet function testing to adjust antiplatelet therapy for elective coronary stenting: a landmark analysis of the ARCTIC trial (2013) (304)
Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial (2014) (283)
Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial (2011) (282)
Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. (2009) (282)
Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial (2016) (281)
Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. (2004) (276)
Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction (2001) (268)
Prehospital ticagrelor in ST-segment elevation myocardial infarction. (2014) (266)
Prehospital ticagrelor in ST-segment elevation myocardial infarction. (2014) (265)
International Expert Consensus on Switching Platelet P2Y12 Receptor–Inhibiting Therapies (2017) (264)
Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up. (2007) (252)
Myocardial Viability in Patients With Q Wave Myocardial Infarction and No Residual Ischemia (1992) (251)
Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. (1998) (250)
One‐Year Outcomes after PCI Strategies in Cardiogenic Shock (2018) (249)
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial (2010) (238)
Device-Related Thrombosis After Percutaneous Left Atrial Appendage Occlusion for Atrial Fibrillation. (2018) (225)
Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris (2001) (218)
Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk (2008) (215)
Drug eluting stents: an updated meta-analysis of randomised controlled trials (2005) (212)
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. (2012) (202)
Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. (2011) (198)
Statin therapy is associated with lower prevalence of gut microbiota dysbiosis (2020) (186)
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. (2015) (183)
Aspirin to Prevent Cardiovascular Disease: The Association of Aspirin Dose and Clopidogrel With Thrombosis and Bleeding (2009) (183)
PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study. (2010) (178)
Acute Release of Plasminogen Activator Inhibitor-1 in ST-Segment Elevation Myocardial Infarction Predicts Mortality (2003) (175)
Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis (2012) (174)
High Plasma Aldosterone Levels on Admission Are Associated With Death in Patients Presenting With Acute ST-Elevation Myocardial Infarction (2006) (174)
Predictors of Bleeding and Time Dependence of Association of Bleeding With Mortality: Insights From the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel—Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) (2011) (172)
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial (2017) (166)
Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. (2001) (163)
The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis. (2005) (160)
Low molecular weight heparin after mechanical heart valve replacement. (2000) (156)
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome (2009) (153)
Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin (2004) (150)
Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes: The Lessons From Antagonizing the Cellular Effects of Thrombin–Acute Coronary Syndromes Trial (2011) (147)
Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. (2006) (146)
A Structural and Dynamic Investigation of the Facilitating Effect of Glycoprotein IIb/IIIa Inhibitors in Dissolving Platelet-Rich Clots (2002) (145)
Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. (2016) (145)
Anticoagulants in heart disease: current status and perspectives. (2007) (143)
Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. (2005) (142)
Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. (2008) (139)
Can we override clopidogrel resistance? (2009) (136)
Integrating Genome-Wide Genetic Variations and Monocyte Expression Data Reveals Trans-Regulated Gene Modules in Humans (2011) (134)
Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. (2014) (134)
High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). (2011) (133)
Dynamic Changes of Fibrin Architecture during Fibrin Formation and Intrinsic Fibrinolysis of Fibrin-rich Clots* (2003) (133)
Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials (2017) (131)
Smoking, Clopidogrel, and Mortality in Patients With Established Cardiovascular Disease (2009) (131)
Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. (2000) (130)
High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. (2012) (130)
New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis. (2010) (127)
Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. (2008) (126)
A unique, low dose of intravenous enoxaparin in elective percutaneous coronary intervention. (2002) (125)
The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale. (2009) (125)
Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. (2007) (124)
CYP2C19 But Not PON1 Genetic Variants Influence Clopidogrel Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy in Post–Myocardial Infarction Patients (2011) (124)
Unprotected left main revascularization in patients with acute coronary syndromes. (2009) (120)
Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. (2009) (120)
Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). (2009) (119)
Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. (2004) (119)
Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. (2004) (116)
Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. (2007) (115)
Periprocedural myocardial infarction and injury in elective coronary stenting (2018) (114)
Management of cardiogenic shock complicating myocardial infarction (2018) (114)
Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. (1993) (113)
Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: JACC State-of-the-Art Review. (2019) (111)
Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. (2009) (111)
Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention: The SEPIA-PCI Trial (2007) (109)
Fibrinogen after coronary angioplasty as a risk factor for restenosis. (1995) (108)
The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). (2006) (107)
The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. (2012) (107)
Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. (2004) (107)
Disaggregation of In Vitro Preformed Platelet-Rich Clots by Abciximab Increases Fibrin Exposure and Promotes Fibrinolysis (2001) (103)
A preferred reperfusion strategy for acute myocardial infarction. (2003) (103)
Oral anti‐Xa anticoagulation after trans‐aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial (2018) (102)
The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. (2007) (100)
Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. (2017) (100)
Duration of Dual Antiplatelet Therapy After Coronary Stenting: A Review of the Evidence. (2015) (99)
Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals. (2009) (98)
Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failure. (2012) (97)
P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction (2015) (95)
Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. (2019) (94)
Coronavirus Disease 2019–Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management (2020) (93)
Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. (2008) (92)
Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus. (2020) (92)
Enoxaparin in unstable angina patients with renal failure. (2001) (91)
Corrigendum to: ‘2013 ESC guidelines on the management of stable coronary artery disease’ (2014) (88)
Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study. (2008) (87)
Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction. (2021) (87)
Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. (2016) (87)
Reperfusion in patients with renal dysfunction after presentation with ST-segment elevation or left bundle branch block: GRACE (Global Registry of Acute Coronary Events). (2009) (87)
&bgr;-Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction: Post Hoc Analysis From the CHARISMA Trial (2014) (87)
Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial. (2016) (86)
Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis (2014) (85)
Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. (1998) (85)
Long-Term Mortality and Early Valve Dysfunction According to Anticoagulation Use: The FRANCE TAVI Registry. (2019) (84)
Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose: The Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) Study (2008) (84)
The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndro (2005) (84)
Best Practices for the Prevention of Radial Artery Occlusion After Transradial Diagnostic Angiography and Intervention: An International Consensus Paper. (2019) (82)
Plasma homocysteine and the extent of atherosclerosis in patients with coronary artery disease. (1997) (81)
Fibrinogen as a risk factor for coronary heart disease. (1998) (80)
Late Consequences of Acute Coronary Syndromes: Global Registry of Acute Coronary Events (GRACE) Follow-up. (2015) (80)
Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction (the ARMADA study). (2003) (80)
Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events. (2005) (79)
Dosing Strategy in Patients with Renal Failure Receiving Enoxaparin for the Treatment of non‐ST‐segment Elevation Acute Coronary Syndrome (2005) (77)
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. (2007) (77)
Effects of Abciximab on the Architecture of Platelet-Rich Clots in Patients With Acute Myocardial Infarction Undergoing Primary Coronary Intervention (2001) (77)
Pre-hospital reperfusion therapy: a strategy to improve therapeutic outcome in patients with ST-elevation myocardial infarction. (2005) (76)
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. (2013) (76)
Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial. (2010) (75)
Influence of &ggr;′ Fibrinogen Splice Variant on Fibrin Physical Properties and Fibrinolysis Rate (2004) (75)
Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology (2020) (74)
Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. (2015) (74)
Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial (2005) (74)
Does Preoperative Coronary Angioplasty Improve Perioperative Cardiac Outcome? (2005) (73)
Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study. (2014) (71)
Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. (2017) (70)
Coronavirus Disease 2019 Acute Myocarditis and Multisystem Inflammatory Syndrome in Adult Intensive and Cardiac Care Units (2020) (70)
High cardiovascular event rates in patients with asymptomatic carotid stenosis: the REACH registry * (2009) (70)
1-year survival in a randomized trial of facilitated reperfusion: results from the FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial. (2009) (69)
Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events (2009) (68)
Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. (2007) (67)
Efficacy of Ex Vivo Autologous and In Vivo Platelet Transfusion in the Reversal of P2Y12 Inhibition by Clopidogrel, Prasugrel, and Ticagrelor: The APTITUDE Study (2015) (67)
Switching acute coronary syndrome patients from prasugrel to clopidogrel. (2013) (66)
Sustained Ventricular Tachycardia and Ventricular Fibrillation Complicating Non–ST-Segment–Elevation Acute Coronary Syndromes (2012) (66)
Systematic primary aspiration in acute myocardial percutaneous intervention: a multicentre randomised controlled trial of the export aspiration catheter. (2008) (66)
Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT‐HF randomized phase 2 trial (2017) (64)
Genetic substudy of the PLATO trial (2011) (64)
Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. (2004) (64)
Impact of red blood cell transfusion on platelet activation and aggregation in healthy volunteers: results of the TRANSFUSION study. (2010) (64)
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials. (2003) (64)
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus. (2002) (64)
Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective. (2010) (64)
Anomalous coronary arteries coursing between the aorta and pulmonary trunk: clinical indications for coronary artery bypass. (1991) (62)
Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. (2005) (61)
Ischemia-modified albumin levels predict long-term outcome in patients with acute myocardial infarction. The French Nationwide OPERA study. (2010) (61)
CPAP for acute cardiogenic pulmonary oedema from out-of-hospital to cardiac intensive care unit: a randomised multicentre study (2011) (60)
Pre-hospital detection of acute myocardial infarction with ultra-rapid human fatty acid-binding protein (H-FABP) immunoassay. (2007) (60)
Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease (2020) (58)
Unusual arterial thrombotic events in Covid-19 patients (2020) (57)
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. (2008) (57)
Premature withdrawal and alternative therapies to dual oral antiplatelet therapy (2006) (56)
Renal function, atherothrombosis extent, and outcomes in high-risk patients. (2009) (55)
Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study). (2004) (55)
Fetuin-A is an independent predictor of death after ST-elevation myocardial infarction. (2007) (55)
Effect of Renal Function on the Pharmacokinetics of Enoxaparin and Consequences on Dose Adjustment (2004) (55)
Association of Serum Cholesterol Efflux Capacity With Mortality in Patients With ST-Segment Elevation Myocardial Infarction. (2018) (54)
Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elev (2013) (53)
A direct comparison of intravenous enoxaparin with unfractionated heparin in primary percutaneous coronary intervention (from the ATOLL trial). (2013) (53)
Delay to angiography and outcomes following presentation with high-risk, non-ST-elevation acute coronary syndromes: results from the Global Registry of Acute Coronary Events (2008) (52)
Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. (2016) (51)
Prevalence and clinical impact of Upper Gastrointestinal Symptoms in subjects treated with low dose aspirin: the UGLA survey. (2012) (51)
Effect of prior exposure to Chlamydia pneumoniae, Helicobacter pylori, or cytomegalovirus on the degree of inflammation and one-year prognosis of patients with unstable angina pectoris or non-Q-wave acute myocardial infarction. (2000) (51)
Sharing Data from Cardiovascular Clinical Trials--A Proposal. (2016) (50)
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial (2020) (50)
P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. (2016) (50)
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial (2020) (50)
Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. (2011) (49)
Rationale for an early aldosterone blockade in acute myocardial infarction and design of the ALBATROSS trial. (2010) (49)
Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). (2018) (48)
Ambulatory transradial percutaneous coronary intervention: A safe, effective, and cost‐saving strategy (2013) (48)
The acute reperfusion management of STEMI in patients with impaired glucose tolerance and type 2 diabetes (2005) (48)
The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. (2008) (48)
Microparticles and sudden cardiac death due to coronary occlusion. The TIDE (Thrombus and Inflammation in sudden DEath) study (2015) (48)
Long-Term Evolution of Premature Coronary Artery Disease. (2019) (48)
Performance comparison of two microarray platforms to assess differential gene expression in human monocyte and macrophage cells (2008) (47)
Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In (2014) (47)
High On-Treatment Platelet Reactivity as a Risk Factor for Secondary Prevention After Coronary Stent Revascularization: A Landmark Analysis of the ARCTIC Study (2014) (46)
Population pharmacokinetic‐pharmacodynamic analysis of fluindione in patients (1998) (46)
Thromboxane receptor blockade prevents pulmonary hypertension induced by heparin-protamine reactions in awake sheep. (1990) (46)
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). (2010) (45)
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention 1-year results from the STEEPLE (SafeTy and efficacy of enoxaparin in percutaneous coronary intervention patients, an international randomized evaluation) trial. (2009) (45)
Upstream Clopidogrel Use and the Efficacy and Safety of Early Eptifibatide Treatment in Patients With Acute Coronary Syndrome: An Analysis From the Early Glycoprotein IIb/IIIa Inhibition in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) Trial (2011) (44)
Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in (2015) (44)
Regional Patterns of Use of a Medical Management Strategy for Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: Insights From the EARLY ACS Trial (2012) (44)
Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention. (2019) (44)
REACH: international prospective observational registry in patients at risk of atherothrombotic events. Results for the French arm at baseline and one year. (2008) (43)
Prasugrel monitoring and bleeding in real world patients. (2013) (43)
Pretreatment with P2Y12 Inhibitors in Non–ST-Segment–Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy (2014) (43)
Relation between body mass index, waist circumference, and cardiovascular outcomes in 19,579 diabetic patients with established vascular disease: the REACH Registry (2012) (42)
Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. (2013) (41)
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials (2021) (41)
Contrast-induced acute kidney injury and mortality in ST elevation myocardial infarction treated with primary percutaneous coronary intervention (2017) (41)
Impact of aspirin with or without clopidogrel on postoperative bleeding and blood transfusion in coronary surgical patients treated prophylactically with a low-dose of aprotinin. (2007) (41)
Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial (2007) (40)
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. (2005) (40)
Relation of timing of cardiac catheterization to outcomes in patients with non-ST-segment elevation myocardial infarction or unstable angina pectoris enrolled in the multinational global registry of acute coronary events. (2005) (38)
Preserving cardiac function in the hypertensive patient: why renal parameters hold the key. (2005) (38)
An education program for risk factor management after an acute coronary syndrome: a randomized clinical trial. (2014) (38)
Cardiac procedural myocardial injury, infarction, and mortality in patients undergoing elective percutaneous coronary intervention: a pooled analysis of patient-level data. (2020) (37)
Anticoagulation in coronary intervention. (2016) (37)
Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. (2005) (35)
Low‐molecular‐weight heparin vs. unfractionated heparin in percutaneous coronary intervention: A combined analysis (2005) (35)
Ticagrelor in the renal dysfunction subgroup: subjugated or substantiated? (2010) (35)
Evaluation of Thromboxane Production and Complement Activation During Myocardial Ischemia in Patients With Angina Pectoris (1991) (35)
Effects of ultrasound energy on thrombi in vitro. (1993) (34)
Usefulness of biomarker strategy to improve GRACE score's prediction performance in patients with non-ST-segment elevation acute coronary syndrome and low event rates. (2010) (34)
Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events-Angiographic) study. (2010) (34)
Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. (2009) (33)
Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia. (2013) (33)
Slow response to clopidogrel predicts low response. (2010) (33)
Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. (2010) (33)
Dual antiplatelet therapy: optimal timing, management, and duration. (2015) (32)
A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. (2011) (32)
Increasing use of single and combination medical therapy in patients hospitalized for acute myocardial infarction in the 21st century: a multinational perspective. (2007) (32)
Images in cardiovascular medicine. Architecture of intracoronary thrombi in ST-elevation acute myocardial infarction: time makes the difference. (2006) (32)
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. (2019) (32)
Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved European label: insights from PEGASUS-TIMI 54 (2019) (31)
Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study (2015) (31)
Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention (2011) (31)
Prehospital Abciximab in ST-Segment Elevation Myocardial Infarction: Results of the Randomized, Double-Blind MISTRAL Study (2012) (30)
Neutralization of low molecular weight heparin by polybrene prevents thromboxane release and severe pulmonary hypertension in awake sheep. (1990) (30)
Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction: The ATLANTIC-H²⁴ Analysis. (2015) (30)
Aldosterone, atherosclerosis and vascular events in patients with stable coronary artery disease. (2013) (29)
Anaemia to predict outcome in patients with acute coronary syndromes. (2013) (28)
Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes. (2004) (28)
One-year clinical outcomes of the STENTYS Self-Apposing¨ coronary stent in patients presenting with ST-segment elevation myocardial infarction: results from the APPOSITION III registry. (2015) (28)
A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study. (2011) (28)
Frequency and Impact of Bleeding on Outcome in Patients With Cardiogenic Shock. (2020) (28)
Review: Platelet Function Testing and Implications for Clinical Practice (2009) (28)
Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy. (2016) (27)
Beta-blocker use in ST-segment elevation myocardial infarction in the reperfusion era (GRACE). (2014) (27)
Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes (2017) (27)
Oral dual antiplatelet therapy: what have we learnt from recent trials? (2015) (27)
Arteriolar vasoconstriction and tachyphylaxis with intraarterial angiotensin II. (1989) (27)
Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low dose aspirin. (1994) (27)
Summary of recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction (2004) (26)
Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. (2010) (26)
Contrast-induced nephropathy: the sin of primary percutaneous coronary intervention? (2014) (26)
Updates and current recommendations for the management of patients with non-ST-elevation acute coronary syndromes: what it means for clinical practice. (2015) (26)
Measuring and targeting aldosterone and renin in atherosclerosis-a review of clinical data. (2011) (26)
Bleeding complications in primary percutaneous coronary intervention of ST‐elevation myocardial infarction in a radial center (2012) (26)
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study (2017) (26)
A rise of troponin and/or von Willebrand factor over the first 48 h is associated with a poorer 1-year outcome in unstable angina patients. (2000) (26)
Endothelin-1 in patients with coronary heart disease undergoing cardiac catheterization. (1994) (26)
Indirect Comparison of the Efficacy and Safety of Alirocumab and Evolocumab: A Systematic Review and Network Meta-Analysis. (2020) (26)
Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study (2011) (25)
Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P 450 2 C 19 * 2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration (25)
STENTYS Self-Apposing sirolimus-eluting stent in ST-segment elevation myocardial infarction: results from the randomised APPOSITION IV trial. (2016) (25)
Optimal Duration of Dual Antiplatelet Therapy After DES Implantation (2016) (25)
Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors. (2013) (25)
Outcome after revascularisation of acute myocardial infarction with cardiogenic shock on extracorporeal life support. (2018) (24)
Sex-Specific Management in Patients With Acute Myocardial Infarction and Cardiogenic Shock (2020) (24)
The efficacy of early versus delayed P2Y12 inhibition in percutaneous coronary intervention for ST-elevation myocardial infarction: a systematic review and meta-analysis. (2018) (24)
Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on‐treatment platelet reactivity (2016) (24)
Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. (2014) (24)
Prognostic and Practical Validation of Current Definitions of Myocardial Infarction Associated With Percutaneous Coronary Intervention. (2018) (24)
Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study (2017) (24)
Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). (2007) (23)
Sonomicrometric regional diaphragmatic shortening in awake sheep after thoracic surgery. (1989) (23)
Stent thrombosis: who's guilty? (2009) (23)
Comparison of various methods for quantitative evaluation of myocardial infarct volume from magnetic resonance delayed enhancement data. (2013) (23)
Transradial versus transfemoral approach for percutaneous coronary intervention in cardiogenic shock: A radial-first centre experience and meta-analysis of published studies. (2015) (23)
Thrombus composition in sudden cardiac death from acute myocardial infarction. (2017) (23)
Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure (2020) (23)
Abstract 2126: CYP2C19 Genetic Variants and Clinical Outcomes With Clopidogrel: A Collaborative Meta-Analysis (2009) (22)
Architecture of Intracoronary Thrombi in ST-Elevation Acute Myocardial Infarction (2006) (22)
Outcomes from patients with multi‐vessel disease following primary PCI (2011) (21)
Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience. (2009) (21)
Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (RIVER-PCI) trial. (2013) (21)
Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine (2018) (21)
Nafamstat mesilate attenuates pulmonary hypertension in heparin-protamine reactions. (1989) (21)
Lithium causing a serious sinus‐node dysfunction at therapeutic doses (1984) (21)
Age and benefit of early coronary angiography after out-of-hospital cardiac arrest in patients presenting with shockable rhythm: Insights from the Sudden Death Expertise Center registry. (2018) (21)
Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: The randomized AMERICA Study. (2018) (21)
Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. (2018) (21)
Systemic embolism as a complication of percutaneous mitral valvuloplasty. (1992) (20)
Effects of ultrasound energy on total peripheral artery occlusions: initial angiographic and angioscopic results. (1993) (20)
Value of Antiplatelet Therapy in Preventing Thrombotic Events in Generalized Vascular Disease (2000) (20)
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. (2021) (20)
Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events. (2010) (20)
Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study. (2014) (20)
FXIII-A Leu34 genetic variant in premature coronary artery disease: A genotype – phenotype case control study (2011) (20)
Impact of prior statin therapy on arrhythmic events in patients with acute coronary syndromes (from the Global Registry of Acute Coronary Events [GRACE]). (2009) (20)
Relation of high concentrations of plasma carboxy-terminal telopeptide of collagen type I with outcome in acute myocardial infarction. (2009) (19)
Educational Impact on Apixaban Adherence in Atrial Fibrillation (the AEGEAN STUDY): A Randomized Clinical Trial (2019) (19)
Mineralocorticoid receptor antagonists in patients with acute myocardial infarction — A systematic review and meta‐analysis of randomized trials (2018) (19)
Copeptin as a prognostic biomarker in acute myocardial infarction. (2019) (19)
High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial (2011) (19)
Guía de Práctica Clínica de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquémica estable (2014) (19)
Serious sinus node dysfunction caused by therapeutic doses of lithium. (1984) (19)
Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial. (2020) (19)
Device-Related Thrombus After Left Atrial Appendage Closure (2021) (18)
Sex-related differences after contemporary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. (2015) (18)
Glycoprotein IIb/IIIa Inhibition—Reply (2004) (18)
Coronary revascularization in the diabetic patient. (2014) (18)
Pharmacogenetics of clopidogrel. (2012) (18)
Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction (2018) (18)
Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program (2012) (17)
Cardiac events after low osmolar ionic or isosmolar nonionic contrast media utilization in the current era of coronary angioplasty (2006) (17)
Factors Associated With Infarct-Related Artery Patency Before Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the FAST-MI 2010 Registry). (2016) (17)
Effect of platelet depletion on lung vasoconstriction in heparin-protamine reactions. (1989) (17)
[Hyperhomocysteinemia in coronary artery diseases. Apropos of a study on 102 patients]. (1996) (17)
Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery: A Randomized Controlled Trial (2012) (17)
Observational study of adherence to European clinical practice guidelines for the management of acute coronary syndrome in revascularized versus non-revascularized patients - the CONNECT Study. (2010) (17)
Long-term outcome after bare-metal or drug-eluting stenting for allograft coronary artery disease. (2010) (17)
Effect of irbesartan and enalapril in non-ST elevation acute coronary syndrome: results of the randomized, double-blind ARCHIPELAGO study. (2009) (16)
Impact of transfer time on mortality in acute coronary syndrome with ST-segment elevation treated by angioplasty. (2012) (16)
Guía de práctica clínica de la ESC sobre revascularización miocárdica, 2014 (2015) (16)
Head-to-head comparison of the diagnostic performances of Rubidium-PET and SPECT with CZT camera for the detection of myocardial ischemia in a population of women and overweight individuals (2018) (16)
Homocysteine: the new player in the field of coronary risk. (1996) (16)
Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC Trial (2019) (16)
[Expert consensus document on the use of antiplatelet agents]. (2004) (16)
Real-life management of dual antiplatelet therapy interruption: the REGINA survey. (2009) (16)
Acute myocardial infarction after oral tranexamic acid treatment initiation. (2002) (16)
Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study. (2020) (16)
Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction (ACCOAST) study. (2015) (15)
Cardiovascular manifestations of sickle cell disease. (2020) (15)
Modeling INR data to predict maintenance fluindione dosage. (1998) (15)
One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent. (2011) (15)
The P2Y12 receptor as a target of antithrombotic drugs (2011) (15)
Angiopoietin-like 4 serum levels on admission for acute myocardial infarction are associated with no-reflow. (2013) (15)
Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction. (2019) (15)
Routine CYP2C19 genotyping to adjust antiplatelet therapy (2020) (15)
Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial (2009) (15)
Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel (2015) (15)
Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial. (2017) (14)
Development and validation of a bleeding risk model for patients undergoing elective percutaneous coronary intervention. (2011) (14)
Very early screening for sleep-disordered breathing in acute coronary syndrome in patients without acute heart failure. (2014) (14)
The year in cardiology 2015: acute coronary syndromes. (2016) (14)
FACT : registre national français des syndromes coronaires aigus.: Étude particulière des centres hospitaliers généraux français (2003) (14)
Incidence, delays, and outcomes of STEMI during COVID‐19 outbreak: Analysis from the France PCI registry (2020) (14)
Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation: A Pairwise Meta-Analysis of 6 Trials and 21 457 Patients (2019) (14)
The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial. (2009) (14)
Mechanical reperfusion: treat well, treat on time too (2008) (14)
Predictive Value of the Residual SYNTAX Score in Patients With Cardiogenic Shock. (2021) (14)
Stenting and glycoprotein IIb/IIIa inhibition in patients with acute myocardial infarction undergoing percutaneous coronary intervention: Findings from the global registry of acute coronary events (GRACE) (2003) (14)
Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention. (2015) (14)
Does the polymorphism 677C-T of the 5,10-methylenetetrahydrofolate reductase gene contribute to homocysteine-related vascular disease? (1998) (14)
Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome (2015) (13)
Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach (2019) (13)
On- Versus Off-Hours Presentation and Mortality of ST-Segment Elevation Myocardial Infarction Patients Treated With Primary Percutaneous Coronary Intervention. (2019) (13)
Lowering mortality in ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: key prehospital and emergency room treatment strategies (2009) (13)
Antithrombotic therapy before, during and after emergency angioplasty for ST elevation myocardial infarction (2017) (13)
Anticoagulation in Acute Coronary Syndrome-State of the Art. (2018) (13)
Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations. (2015) (13)
Thienopyridine-Associated Drug-Drug Interactions: Pharmacologic Mechanisms and Clinical Relevance (2011) (13)
Uaktualnione stanowisko ESC dotyczące stosowania podwójnej terapii przeciwpłytkowej w chorobie wieńcowej w 2017 roku, przygotowane we współpracy z EACTS (2017) (12)
An evidence-based review of current anti-platelet options for STEMI patients. (2013) (12)
Do Patients need Lifelong β-Blockers after an Uncomplicated Myocardial Infarction? (2019) (12)
Phenotypic Heterogeneity of Fulminant COVID-19--Related Myocarditis in Adults (2022) (12)
Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY). (2014) (12)
Low Molecular Weight Heparins in the Cardiac Catheterization Laboratory (1999) (12)
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients (2015) (12)
Platelet Biology and Implications for Antiplatelet Therapy in Atherothrombotic Disease (2011) (12)
Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome (2015) (12)
Abstract 3007: Glycoprotein IIb/IIIa Inhibitors before Primary Percutaneous Coronary Intervention of ST-Elevation Myocardial Infarction Improve Perfusion and Outcomes: Insights from APEX-AMI (2007) (12)
Optimal Use of Thienopyridines in Non-ST-Elevation Acute Coronary Syndrome Following CURRENT-OASIS 7 (2011) (11)
Prognostic Value of SYNTAX Score in Patients With Infarct-Related Cardiogenic Shock: Insights From the CULPRIT-SHOCK Trial. (2020) (11)
2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations. (2020) (11)
Double‐Dose Versus Standard‐Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (2017) (11)
[FACT: French national registry of acute coronary syndromes. Specific study of French general hospital centers]. (2003) (11)
Differences Among Low-Molecular-Weight Heparins: Evidence in Patients With Acute Coronary Syndromes (2009) (11)
Interleukin-1Beta and Risk of Premature Death in Patients with Myocardial Infarction. (2020) (11)
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. (2019) (11)
2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region (2021) (11)
Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement: The ATLANTIS-4D-CT Randomized Clinical Trial Substudy. (2022) (11)
Incidence of, risk factors for and impact of readmission for heart failure after successful transcatheter aortic valve implantation. (2019) (11)
Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay (2013) (10)
Predictors and implications of Q-waves in ST-elevation acute coronary syndromes. (2009) (10)
Bedside monitoring of antiplatelet therapy for coronary stenting. (2013) (10)
The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). (2012) (10)
Clopidogrel and CYP2C19 testing: ready for clinical prime time? (2012) (10)
Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial). (2014) (10)
The use of GP IIb/IIIa inhibitors into new perspectives: pre-catheterization laboratory administration (2005) (10)
Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit? (2009) (10)
Economic Evaluation of Enoxaparin Sodium versus Heparin in Unstable Angina (2000) (10)
US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins (2012) (10)
Early Aspirin Discontinuation Following Acute Coronary Syndrome or Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2020) (10)
Imaging the ovine heparin-protamine interaction with 111In-protamine. (1993) (10)
[Mitral valvuloplasty during the 4th month of pregnancy. Fetal protection with a lead mantle]. (1991) (10)
Incidence and consequence of major bleeding in primary percutaneous intervention for ST-elevation myocardial infarction in the era of radial access: an analysis of the international randomized Acute myocardial infarction Treated with primary angioplasty and intravenous enoxaparin Or unfractionated h (2015) (10)
Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial (2020) (10)
Medium-term survival after primary angioplasty for myocardial infarction complicated by cardiogenic shock after the age of 75 years. (2008) (10)
Biomarkers of Thrombosis in ST-Segment Elevation Myocardial Infarction: A Substudy of the ATOLL Trial Comparing Enoxaparin Versus Unfractionated Heparin (2018) (10)
Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction. (2015) (10)
Antithrombotic and antiplatelet therapy in TAVI patients: a fallow field? (2013) (10)
Adrenomedullin and Arterial Stiffness: Integrative Approach Combining Monocyte ADM Expression, Plasma MR-Pro-ADM, and Genome-Wide Association Study (2014) (10)
Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial (2019) (10)
Antiplatelet therapy and coronary artery bypass graft surgery a fallow land. (2010) (10)
Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study (2014) (10)
067 CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics and clinical efficacy in post-myocardial infarction patients (2012) (10)
P2Y12 inhibitors (2009) (10)
Acute Multivessel Coronary Occlusion Revealing COVID-19 in a Young Adult (2020) (10)
Rare genotypes of protein Z gene are a risk factor for premature myocardial infarction but not protein Z plasma level (2009) (10)
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. (2022) (9)
Radial versus femoral artery access for percutaneous coronary artery intervention in patients with acute myocardial infarction and multivessel disease complicated by cardiogenic shock: Subanalysis from the CULPRIT-SHOCK trial. (2020) (9)
Impact of anticoagulation on ionic and nonionic contrast media effect on thrombogenesis and fibrinolysis: The PEPCIT study (2012) (9)
Characteristics and prognosis of patients with angiographic stent thrombosis: comparison between drug-eluting and bare-metal stents. (2008) (9)
IMPACT OF MORPHINE ADMINISTRATION ON TICAGRELOR-INDUCED PLATELET INHIBITION IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS TREATED BY PRIMARY PCI: RESULTS FROM THE PRIVATE-ATLANTIC STUDY (2015) (9)
Diagnosis of primary cardiac sarcoma. Report of 4 cases and review of the literature. (1988) (9)
Catheter-related thrombosis: biological and clinical evidence for risk with currently available anticoagulants. (2008) (9)
Rationale and design of the Flow Evaluation to Guide Revascularization in Multivessel ST-Elevation Myocardial Infarction (FLOWER-MI) trial. (2019) (9)
Ticagrelor to prevent restenosis: new drug for an old hypothesis? (2010) (9)
Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials (2017) (9)
P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. (2019) (9)
Cerebral Embolism: A Silent Iatrogenic Complication of TAVR That Needs Voiced Consideration. (2016) (9)
Cytochrome P450 2C19 polymorphism and clopidogrel after MI – Authors' reply (2009) (9)
Clinical manifestations and outcomes of coronavirus disease‐19 in heart transplant recipients: a multicentre case series with a systematic review and meta‐analysis (2021) (8)
Impact of preprocedural TIMI flow on clinical outcome in low‐risk patients with ST‐elevation myocardial infarction: Results from the ATLANTIC study (2020) (8)
Long-term follow-up of patients with sirolimus-eluting stents for treatment of bare-metal in-stent restenosis. (2010) (8)
Spontaneous late improvement of myocardial viability in the chronic infarct zone is possible, depending on persistent TIMI 3 flow and a low grade stenosis of the infarct artery (1999) (8)
CYP 2 C 19 But Not PON 1 Genetic Variants Influence Clopidogrel Pharmacokinetics , Pharmacodynamics , and Clinical Efficacy in Post – Myocardial Infarction Patients (2011) (8)
Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients Undergoing Primary Percutaneous Coronary Intervention (2017) (8)
COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial. (2020) (8)
Supraventricular Arrhythmia Following Patent Foramen Ovale Percutaneous Closure. (2022) (8)
APPOSITION V: STENTYS coronary stent system clinical trial in subjects with ST-segment elevation myocardial infarction--rationale and design. (2014) (8)
Duration of ischemia and treatment effects of pre‐ versus in‐hospital ticagrelor in patients with ST‐segment elevation myocardial infarction: Insights from the ATLANTIC study (2018) (8)
Abstract 18842: Adherence and Persistence to Apixaban Treatment in Patients With Non Valvular Atrial Fibrillation is High and Similar With Standard of Care Patient Education or With an Additional Educational Program: The Randomized AEGEAN Study (2016) (8)
Early thromboxane release during pacing-induced myocardial ischemia with angiographically normal coronary arteries. (1990) (8)
Aldosterone blockade: current research and future trends (2011) (8)
Impact of Chronic Total Occlusion and Revascularization Strategy in Patients with Infarct-Related Cardiogenic Shock A Subanalysis of the CULPRIT-SHOCK trial. (2020) (8)
HIV Infection and Long‐Term Residual Cardiovascular Risk After Acute Coronary Syndrome (2020) (8)
Cardiac procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data (2020) (8)
Corrigendum to: Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data. (2021) (8)
Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction (2004) (8)
Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. (2011) (8)
La maladie athérothrombotique coronaire du sujet jeune : état des lieux (2000) (8)
Prasugrel versus clopidogrel in acute coronary syndromes treated with PCI: Effects on clinical outcome according to culprit artery location. (2016) (7)
Current antiplatelet options for NSTE-ACS patients. (2012) (7)
Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial (2020) (7)
Clinical Outcome of First‐ vs Second‐Generation DES According to DAPT Duration: Results of ARCTIC‐Generation (2016) (7)
Eptifibatide provides additional platelet inhibition in non-ST elevation myocardial infarction patients already treated with aspirin and clopidogrel: Results of the PEACE study (2003) (7)
[Neurohormonal profile in aortic valve stenosis]. (1993) (7)
[Development of an ultrasonic system for the recanalization of coronary arteries]. (1989) (7)
Bronchoscopie souple et antiagrégants plaquettaires : analyse du rapport bénéfices-risques (2007) (7)
Myocardial infarction after endomyocardial biopsy in a heart transplant patient. (2002) (7)
Coronary blood flow reserve measured by contrast media injection depends on myocardial viability. (1991) (7)
Safety and efficacy of adjuvant glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention performed from the radial approach for acute ST segment elevation myocardial infarction. (2013) (7)
Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as biomarkers of acute kidney injury after ST-segment elevation myocardial infarction treated by percutaneous coronary intervention. (2019) (7)
Feasibility of outpatient coronary angiography with "ad hoc" angioplasty. (2008) (7)
Radial access in patients with acute coronary syndrome without persistent ST-segment elevation: Systematic review, collaborative meta-analysis, and meta-regression. (2016) (7)
Predictive factors of cardiac events after implantation of sirolimus-eluting stents for treatment of in-stent restenosis. (2006) (6)
Temporal trends in all-cause mortality according to smoking status: Insights from the Global Registry of Acute Coronary Events. (2016) (6)
Management and outcomes of patients presenting with STEMI by use of chronic oral anticoagulation: results from the GRACE registry (2013) (6)
TCT-78 Efficacy of Long-Term Ticagrelor in Stented Patients in PEGASUS-TIMI 54 (2015) (6)
Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study. (2020) (6)
Cardiac manifestations in sickle cell disease varies with patient genotype (2018) (6)
Lack of platelet-activating factor release during reversible myocardial ischaemia. (1992) (6)
Major Adverse Events With Percutaneous Left Atrial Appendage Closure in Patients With Atrial Fibrillation. (2019) (6)
Predictors of Left Ventricular Dysfunction in Friedreich’s Ataxia in a 16-Year Observational Study (2019) (6)
Transfer for primary angioplasty: who and how? (2002) (6)
Clinical outcomes with the STENTYS self-apposing coronary stent in patients presenting with ST-segment elevation myocardial infarction: two-year insights from the APPOSITION III (A Post-Market registry to assess the STENTYS self-exPanding COronary Stent In AcuTe MyocardIal InfarctiON) registry. (2017) (6)
Intravenous enoxaparin anticoagulation in percutaneous left atrial cardiac procedures. (2017) (6)
Description of modern practices of percutaneous coronary intervention and identification of risk factors for adverse outcome in the French nationwide OPEN registry (2004) (6)
Assessment of early administration of abciximab in acute ST-segment elevation myocardial infarction in the emergency room. (2006) (6)
Que connat-on de la toxicit cardiovasculaire des AINS? (2006) (6)
One-Year Survival After ST-Segment–Elevation Myocardial Infarction in Relation With Prehospital Administration of Dual Antiplatelet Therapy: The FAST-MI Program (2018) (6)
Long-Term Mortality and Early€Valve€Dysfunction According€to€Anticoagulation Use (2019) (6)
Thrombosis after implantation of drug-eluting stents. (2006) (6)
Intra-myocardial haemorrhage following recanalisation of a venous coronary arterial bypass by balloon angioplasty. (1991) (5)
Coronary artery disease Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction : a collaborative meta-analysis of randomized trials (2016) (5)
Potent P2Y12 Inhibitors in Low-Risk Patients: Is There a Medical Need? (2016) (5)
Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment (2018) (5)
Clinical and ultrasound results after aortic valve replacement: intermediate-term follow-up with the St. Jude Medical prosthesis. (1989) (5)
Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice (2010) (5)
Practice patterns and clinical outcomes among non‐ST‐segment elevation acute coronary syndrome (NSTE‐ACS) patients presenting to primary and tertiary hospitals: Insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE‐ACS (EARLY‐ACS) trial (2014) (5)
[Fibrinogen: a cardiovascular risk factor]. (2000) (5)
Comparison of risk prediction models in infarct-related cardiogenic shock. (2021) (5)
Epidemiology, treatment patterns and outcomes in patients with coronary or lower extremity artery disease in France. (2019) (5)
Rupture of a saphenous graft into the right ventricle. (2011) (5)
Évaluation des quatre premières années d'activité d'une unité de soins intensifs cardiologiques pour la prise en charge des syndromes coronaires aigus comparativement aux données régionales du registre GRACE (Global Registry of Acute Coronary Events) (2005) (5)
Sunday, 26 August 2012 (2012) (5)
Regional variation in patients and outcomes in the GLOBAL LEADERS trial. (2020) (5)
Pre‐hospital administration of ticagrelor in diabetic patients with ST‐elevation myocardial infarction undergoing primary angioplasty: A sub‐analysis of the ATLANTIC trial (2018) (5)
Left Atrial Appendage Closure in Atrial Fibrillation. (2018) (5)
2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-risk Chronic Coronary Syndrome (2021) (5)
Life-threatening and major cardiac events during long-distance races: updates from the prospective RACE PARIS registry with a systematic review and meta-analysis. (2020) (5)
Rapid P2Y12 inhibition: still an unmet medical need. (2012) (4)
Correlation between Chlamydia pneumoniae detection from coronary angioplasty balloons and atherosclerosis severity. (2006) (4)
ESC position paper Anticoagulants in heart disease : current status and perspectives ‡ (2007) (4)
Single Versus Dual Antiplatelet Therapy Following TAVR: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (2021) (4)
Author Correction: Imidazole propionate is increased in diabetes and associated with dietary patterns and altered microbial ecology (2020) (4)
Thrombus aspiration and prehospital ticagrelor administration in ST‐elevation myocardial infarction: Findings from the ATLANTIC trial (2018) (4)
Short-term effects of the smoke-free legislation on haemostasis and systemic inflammation due to second hand smoke exposure (2011) (4)
Do we need a new P2Y12 receptor antagonist? (2019) (4)
GP IIb/IIIa inhibition in primary stenting: 'do it early, make it easy'. (2002) (4)
[Whole blood viscosity measurement in acute myocardial infarction: feasibility and significance]. (2001) (4)
Pre-hospital ticagrelor in ST-segment elevation myocardial infarction in the French ATLANTIC population. (2017) (4)
Primary stenting with abciximab in acute myocardial infarction complicated by cardiogenic shock (the ADMIRAL trial) (2002) (4)
Outcomes Associated with Respiratory Failure for Patients with Cardiogenic Shock and Acute Myocardial Infarction: A Substudy of the CULPRIT-SHOCK Trial (2020) (4)
One-Year Clinical Outcomes of Patients Presenting With ST-Segment Elevation Myocardial Infarction Caused by Bifurcation Culprit Lesions Treated With the Stentys Self-Apposing Coronary Stent: Results From the APPOSITION III Study. (2017) (4)
TCT-123 Preliminary safety and efficacy results from the REALISE trial: REnAL denervatIon by ultraSound transcatheter Emission (2013) (4)
Investigator Versus Core Laboratory Evaluation of Coronary Flow and Related Mortality in the CULPRIT-SHOCK Trial. (2019) (4)
Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery. (2015) (4)
Intravenous Clopidogrel (MDCO-157) Compared with Oral Clopidogrel: The Randomized Cross-Over AMPHORE Study (2016) (4)
[Effects of urapidil by intravenous injection on pulmonary circulation and cardiac function in left ventricular failure]. (1993) (4)
Collagen biomarker bioprofiles predicting the antifibrotic response to eplerenone in myocardial infarction: findings from the REMINDER trial (2018) (4)
Safety of the combination of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors: observations from the global registry of acute coronary events (GRACE) (2001) (4)
2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology (2014) (4)
Effect of oral anticoagulation on clinical outcomes and haemodynamic variables after successful transcatheter aortic valve implantation. (2020) (4)
Transcatheter Closure of Patent Foramen Ovale in Older Patients With Cryptogenic Thromboembolic Events (2022) (4)
[Platelet aggregation and antiplatelet agents in acute coronary syndromes]. (2004) (4)
Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction. (2021) (4)
Coronary artery disease in systemic lupus: A case-controlled angiographic study. (2019) (4)
Optimal time for catheterization in NSTE-ACS patients with impaired renal function: insights from the ABOARD Study. (2013) (4)
Long-term secondary prevention after high-risk stenting: a good drug for a bad stent. (2015) (4)
Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis (2020) (4)
Blocking platelets more: are we skating on thin ice? (1998) (4)
Clopidogrel pretreatment effect according to the clinical presentation in patients undergoing percutaneous coronary intervention: a meta-analysis (2013) (3)
Premature coronary artery disease (2012) (3)
Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial. (2013) (3)
Les nouveaux antithrombotiques en pathologie coronaire (1997) (3)
Left atrial high-grade undifferentiated pleomorphic sarcoma protruding through the mitral valve. (2014) (3)
[Coronary stents: 30 years of medical progress]. (2014) (3)
Should Hemoglobin Drop Be Added to Bleeding Classifications in ACS? (2021) (3)
[Use of aspirin in coronary disease]. (1995) (3)
Measuring and reversing the effect of non-vitamin K antagonist oral anticoagulants (NOACs). (2015) (3)
Impact of age on the effect of pre-hospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis (2018) (3)
Diagnosis of pulmonary embolism by transoesophageal echocardiography. (1992) (3)
P5367Indirect comparison of the safety and efficacy of alirocumab and evolocumab: from a comprehensive meta-analysis of 30 randomized controlled trials (2019) (3)
A farewell to aspirin in primary prevention? (2018) (3)
L’agrégation plaquettaire et ses inhibiteurs dans les syndromes coronariens aigus (2004) (3)
Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs Multivessel PCI in Cardiogenic Shock Trial (3)
Prasugrel STEMI subgroup analysis – Authors' reply (2009) (3)
Coronary artery vasomotion in cardiac transplant patients with normal coronary angiograms. (1993) (3)
Acute myocarditis presenting as acute myocardial infarction and sudden death with complete atrioventricular block: Value of antimyosin scintigraphy (1999) (3)
Personalized antiplatelet therapy: the wrong approach? (2013) (3)
[New antiplatelet drugs]. (2008) (3)
Life-threatening and major cardiac events during long-distance races: updates from the prospective RACE PARIS registry with a systematic review and meta-analysis. (2021) (3)
[Fibreoptic bronchoscopy and anti-platelet agents: a risk-benefit analysis]. (2007) (3)
Monday, 27 August 2012 (2012) (3)
REACH : registre observationnel prospectif international chez des patients à risque d’événements athérothrombotiques (2010) (3)
Working Group on Thrombosis (2005) (3)
Modulation of cholesterol efflux capacity in patients with myocardial infarction. (2019) (3)
Pharmacological remodeling of the thrombus architecture. (1999) (3)
Association of Culprit Lesion Location With Outcomes of Culprit-Lesion-Only vs Immediate Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock: A Post Hoc Analysis of a Randomized Clinical Trial. (2020) (3)
Syndromes coronaires aigus (2010) (3)
[Peripheral calcific embolism after percutaneous mitral valvuloplasty]. (1992) (3)
Antiplatelet options for secondary prevention in acute coronary syndromes (2011) (3)
Aspirin-Free Strategies After PCI: Still Not Out of the Twilight. (2019) (3)
The times they are a changin'. (2018) (3)
Angiographic predictors of outcome in myocardial infarction patients presenting with cardiogenic shock: A CULPRIT-SHOCK angiographic substudy. (2020) (3)
015 The CHADS2 score predicts more accurately adverse cardiovascular outcome in atherothrombotic patients without atrial fibrillation than established scores: Insights from the European REACH registry (2010) (3)
Antithrombin treatment in patients with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention (2007) (3)
Altered cardiac reserve is a determinant of exercise intolerance in sickle cell anemia patients. (2021) (3)
Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EUROC-DRT registry (2022) (3)
Non-ST-segment elevation acute coronary syndromes: an algorithm for decision. (2007) (3)
[Myocardial infarction: Role of new antiplatelet agents]. (2011) (3)
Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial (2016) (3)
[Effects of ultrasonic energy on blood clots in vitro]. (1993) (3)
UPFRONT CLOPIDOGREL USE AND THE EFFICACY AND SAFETY OF EARLY EPTIFIBATIDE USE IN PATIENTS WITH ACUTE CORONARY SYNDROME: AN ANALYSIS FROM THE EARLY VERSUS DELAYED PROVISIONAL EPTIFIBATIDE IN ACUTE CORONARY SYNDROMES (EARLY ACS) TRIAL (2010) (3)
GLOBAL LEADERS: looking now at the bigger picture. (2019) (3)
Anticoagulation, the Unknown of the Antithrombotic Equation After Stenting of an Acute Coronary Syndrome. (2019) (3)
Prise en charge de l’infarctus du myocarde : place des nouveaux antiagrégants (2011) (3)
Approach after thrombolytic therapy - invasive versus conservative management - Global Registry of Acute Coronary Events (2002) (3)
Bleeding in the Elderly: Risk Factors and Impact on Clinical Outcomes After an Acute Coronary Syndrome, a Sub-study of the Randomized ANTARCTIC Trial (2021) (3)
Thrombosis and antithrombotic therapy Ischaemic risk and efficacy of ticagrelor in relation to time from P 2 Y 12 inhibitor withdrawal in patients with prior myocardial infarction : insights from PEGASUS-TIMI 54 (2016) (3)
DOUBLE-BLIND, RANDOMIZED, PROSPECTIVE COMPARISON OF A LOADING DOSE OF 60 MG PRASUGREL VERSUS 600 MG CLOPIDOGREL IN THE EARLY TREATMENT PHASE IN PATIENTS WITH ACUTE STEMI SCHEDULED FOR PRIMARY PCI: RESULTS OF THE ETAMI TRIAL (2014) (3)
[Value of biochemistry performed in pre-hospital cardiology]. (2005) (3)
Non-ST-Segment Elevation Acute Coronary Syndrome: The Last Nail in the Coffin of Pre-Treatment. (2020) (3)
Glycoprotein IIb/IIIa inhibition and long-term benefit: the stuff of dreams? (2004) (3)
Chest pain, ST-segment elevation in aVR lead, and high troponin levels. (2009) (3)
Long‐Term Ticagrelor in Patients With Prior Coronary Stenting in the PEGASUS‐TIMI 54 Trial (2021) (3)
Revascularization strategies in acute myocardial infarction: a meta-analysis. (2004) (3)
P5546Clinical impact and predictors of complete ST-segment resolution after primary percutaneous coronary intervention: a subanalysis of the ATLANTIC Trial (2017) (2)
Nitroglycerin-resistant coronary spasm treated with intracoronary linsidomine chlorhydrate (SIN-1). (1990) (2)
Prevention and treatment of premature ischaemic heart disease with European Society of Cardiology Guidelines (2022) (2)
Méthodes de dépistage des localisations artérielles asymptomatiques chez le patient athérothrombotique (2005) (2)
The FINESSE (Facilitated intervention with enhanced reperfusion speed to stop events) trial: Results of the formal low molecular weight heparin substudy (2007) (2)
Kidney in the transformation matrix (2019) (2)
The Cornelian dilemma of quitting DAPT (2021) (2)
Impaired ristocetin–induced Platelet Aggregation in Whole Blood Assessed with a Multiplate© Analyser Suggests a New Mechanism of Antiplatelet Effect of Aspirin and Clopidogrel, (2011) (2)
Clinical outcomes according to ECG presentations in infarct-related cardiogenic shock in CULPRIT-SHOCK. (2020) (2)
Prehospital Diagnosis and Management of Acute Myocardial Infarction (2010) (2)
Images in cardiovascular medicine. Recurrent myocardial infarction in a patient with paroxysmal nocturnal hemoglobinuria. (2003) (2)
P2Y12 RECEPTOR INHIBITION ACCORDING TO PREHOSPITAL ADMINISTRATION OF TICAGRELOR IN PRIMARY PCI FOR ST ELEVATION MYOCARDIAL INFARCTION: THE PRIVATE-ATLANTIC STUDY (2015) (2)
Actualización ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria, desarrollada en colaboración con la EACTS (2018) (2)
Benefit of Facilitated PCI in High Risk ST Elevation MI Patients Presenting to Non-PCI Hospitals (2008) (2)
Role of platelet-activating factor in the ovine heparin-protamine reaction. (1992) (2)
Platelet function test-guided strategy: lost in translation? (2015) (2)
Stents coronaires - 30 ans de progrès médical (2014) (2)
Sarcomes du cœur: A propos de 2 cas (1985) (2)
Coronary Artery Bypass Graft Surgery Guided by FFR: Fraction of the Final Response. (2018) (2)
STEMI and NSTEMI are two distinct pathophysiological entities: reply (2007) (2)
Abstract 9309: Benefit of Prasugrel in ST-Elevation Myocardial Infarction According to Timing of Percutaneous Coronary Intervention: Insight from the TRITON-TIMI 38 Study (2011) (2)
Outcomes Following Patent Foramen Ovale Percutaneous Closure According to the Delay From Last Ischemic Event. (2022) (2)
Quelle dose d'aspirine faut-il prescrire chez les coronariens? (1995) (2)
Benefit of low-dose aspirin in patients with hypertension (2010) (2)
Prévalence des lésions athérothrombotiques asymptomatiques et risques d'événements vasculaires chez des patients ayant une maladie coronaire documentée (2005) (2)
Antiagrégants plaquettaires oraux en pratique quotidienne (2010) (2)
TCT-417 REALISE Trial: Renal Denervation by Ultrasound Transcatheter Emission: Six Month Results (2014) (2)
Benefits for specific subpopulations in TRITON-TIMI 38 (2009) (2)
Recurrent Myocardial Infarction in a Patient With Paroxysmal Nocturnal Hemoglobinuria (2003) (2)
[Screening strategies for the diagnosis of asymptomatic arterial lesions in patients with atherothrombosis]. (2005) (2)
[Development of left ventricular function following aortic valve replacement]. (1988) (2)
[Value of antimyosin monoclonal antibody scintigraphy in the diagnosis of acute myocardial infarction]. (1992) (2)
[Prevalence of asymptomatic atherothrombotic lesions and risk of vascular events in patients with documented coronary artery disease]. (2005) (2)
Novel uses for platelet function testing in the clinical laboratory: where are we now? (2014) (2)
New insights for low dosing with the new P2Y12 inhibitors. (2014) (2)
An annual, prospective, international study of outpatients with cardiovascular disease or risk factors: design and methods of the CardioMonitor registry. (2007) (2)
Prognostic value of longitudinal strain and ejection fraction in Friedreich ataxia. (2021) (2)
Risk Factors for In-Hospital Cardiac Arrest in Patients With ST-Segment Elevation Myocardial Infarction. (2022) (2)
Anticoagulant for primary percutaneous coronary intervention - the last dance for unfractionated heparin? (2012) (2)
Glycoprotein IIb/IIIa inhibitors in the elderly: fear of age or age of fear? (2006) (2)
[Management of acute coronary syndromes in a new French coronary intensive care unit. The first four years of activity in the GRACE registry (Global Registry of Acute Coronary Events)]. (2005) (2)
Glycoprotein IIb/IIIa inhibition. Authors' reply (2004) (1)
Recurrent Hypoxemia and Dizziness in an Elderly Adult Associated with a Patent Foramen Ovale (2012) (1)
Abstract 18034: Clinical, Angiographic and Genetic Determinants of Early Coronary Stent Thrombosis: the ONASSIST Study (2011) (1)
Abstract 17491: Impact of Prehospital Administration of Antithrombotic Medications on Infarct-related Artery Patency in ST-elevation Myocardial Infarction: Results from the FAST-MI 2010 Registry (2014) (1)
Will PIONEER AF-PCI change my practice? (2017) (1)
TCT-13 Final 2-year Results of the APPOSITION III Study Evaluating the Use of the STENTYS Self-apposing Stent for the Treatment of ST-segment Elevation Myocardial Infarction in the Setting of Primary PCI (2014) (1)
IMPACT OF PLATELET TRANSFUSION ON PLATELET ACTIVATION AND AGGREGATION IN CARDIAC SURGERY PATIENTS RECEIVING ASPIRIN AND P2Y12 RECEPTOR ANTAGONISTS (2013) (1)
Interleukin-1Beta and risk of premature death and MACE in patients with myocardial infarction (2020) (1)
[Effects of ultrasound energy on femoral artery occlusion. Angiographic and angioscopic results]. (1993) (1)
Pre-hospital treatment with zalunfiban (RUC-4) in patients with ST- Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Rationale and design of the CELEBRATE trial. (2022) (1)
Clinical characteristics and outcomes of COMPASS eligible patients in France. An analysis from the REACH Registry. (2020) (1)
Multimodality imaging of percutaneous closure of the left atrial appendage. (2006) (1)
A Multi-Biomarker Score for a Global Approach of Risk: Time for a Change? (2022) (1)
P5559The effect of prehospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis (2017) (1)
Postprocedure Anticoagulation in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. (2022) (1)
W1922 Epidemiological Characteristics of Low-Dose Aspirin Treatment and Gastroprotection in France : Results of a Nation-Wide Postal Survey (2008) (1)
Restoration of platelet function with platelet transfusion in cardiac surgery patients on dual antiplatelet therapy (2013) (1)
016 High-on thienopyridine platelet reactivity in elderly coronary patients (2012) (1)
Culprit lesion location and outcomes in patients with multi-vessel disease and infarct-related cardiogenic shock. A core laboratory analysis of the CULPRIT-SHOCK trial. (2020) (1)
Interventional Standby for CABG Surgery: The Reverse Paradigm. (2019) (1)
ESC/EAS Guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2. (2022) (1)
Left atrial appendage occlusion to prevent stroke in sub-optimal warfarin candidates: Current results of the European multicenter registry trial (2005) (1)
Higher on-treatment platelet reactivity and more bleeding complications in the elderly: insight from the ARCTIC study (2013) (1)
W1930 Modalities of Low-Dose Aspirin Treatment and Gastroprotective Strategies in General and Specialty Practice in France (2008) (1)
Is coronary multivessel disease in acute myocardial infarction patients still associated with worse clinical outcomes at 1‐year? (2021) (1)
Any room left for new antiplatelet agents in acute coronary syndrome? (2013) (1)
5262Identifying higher risk patients among the COMPASS-Eligible population: An analysis from the REduction of atherothrombosis for continued health (REACH) Registry (2018) (1)
Myocarde hibernant postinfarctus (1994) (1)
Individualized Modeling Approach for DAPT Duration: Vision or Confusion? (2016) (1)
Response to letter regarding article, “sustained ventricular tachycardia and ventricular fibrillation complicating non–ST-segment elevation acute coronary syndromes”. (2013) (1)
Primary coronary angioplasty after transfer versus on-site thrombolysis in acute myocardial infarction: A meta-analysis (2003) (1)
[The cardiologist and anticoagulants: the heart has its reasons]. (1992) (1)
Results of percutaneous left atrial appendage transcatheter occlusion (PLAATO) in 210 patients (2005) (1)
Reducing the Risk of Vascular Disease: Antiplatelet Therapy in the New Millennium (2000) (1)
[Antithrombotics in pre-hospital phase of acute coronary syndromes]. (2005) (1)
Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis (2021) (1)
to Stop EventsAngiographic) Study FINESSE-ANGIO (Facilitated Intervention With Enhanced Reperfusion Speed Function After Facilitated Percutaneous Primary Coronary Angioplasty: The Evaluation of Infarct-Related Coronary Artery Patency and Microcirculatory (2010) (1)
[Review and future perspectives on low-molecular-weight heparin]. (2001) (1)
1137-99 Clopidogrel in unstable angina patients who would have been excluded from randomized pivotal trials (2004) (1)
P5355Impact of evacetrapib on glyvemic control: results from the accelerate trial (2017) (1)
Heparin/low molecular weight heparin (2007) (1)
Beta-blocker prescription and outcomes in uncomplicated acute myocardial infarction: Insight from the ePARIS registry. (2022) (1)
Economic evaluation of fractional flow reserve-guided versus angiography-guided multivessel revascularisation in ST-segment elevation myocardial infarction patients in the FLOWER-MI randomised trial. (2022) (1)
Explorations cardiaques chez l’hémodialysé et le transplanté rénal (2005) (1)
Prise en charge du syndrome coronaire aigu à la phase aiguë (2007) (1)
Abstract 18797: Clinical Impact of High on-Prasugrel Platelet Reactivity in an Acute Coronary Syndrome Population (2012) (1)
Defining standards of care for facilitated and direct percutaneous coronary intervention (2002) (1)
Abbreviated or Standard Antiplatelet Therapy in HBR Patients: Final 15-Month Results of the MASTER-DAPT Trial. (2023) (1)
Measures of Platelet Activation and Aggregation (2006) (1)
The Triple Challenge of Triple Therapy. (2016) (1)
Low molecular weight heparin use in percutaneous coronary intervention. (2002) (1)
Cost-Effectiveness of a Novel Self-Apposing Stent in ST-Segment Elevation Myocardial Infarction (STEMI) in France (2015) (1)
IMPACT OF RESIDUAL INFLAMMATORY RISK IN PATIENTS WITH LOW LDL-CHOLESTEROL UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: INSIGHT FROM A LARGE SINGLE-CENTER REGISTRY (2019) (1)
Circulation CLINICALINVESTIGATION Regular Physical Exercise andLow-Fat Diet: Effects onProgression ofCoronary Artery Disease (1992) (1)
Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy: Pharmacodynamic Insights From the ARCTIC Study. (2019) (1)
017 Incidence, type and prognostic impact of bleeding complications with radial primary PCI of STEMI: The Pitié-Salpêtrière experience (2010) (1)
[The value of active stents for coronary angioplasty in patients with chronic renal failure]. (2006) (1)
Post-procedure anticoagulation in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (2021) (1)
Impact of Center Volume on Outcomes in Myocardial Infarction Complicated by Cardiogenic Shock: A CULPRIT‐SHOCK Substudy (2021) (1)
Antithrombotic Therapy and Cardiovascular Outcomes After Transcatheter Aortic Valve Implantation in Patients Without Indications for Chronic Oral Anticoagulation: A systematic review and network meta-analysis of randomized controlled trials. (2023) (1)
P961Investigator versus Core Lab evaluation of coronary blood flow in PCI of patients in cardiogenic shock: a substudy of the CULPRIT-SHOCK trial (2019) (1)
L’hypothermie thérapeutique, ses différentes applications en pratique clinique (2006) (1)
0466: Point-of-care genetic profiling in acute coronary syndrome (2015) (1)
Pre-hospital treatment with zalunfiban (RUC-4) in patients with ST- Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Rationale and design of the CELEBRATE trial. (2022) (1)
Does left atrial appendage morphology have any impact on the results of percutaneous closure? (2020) (1)
P5602Impact of preprocedural TIMI flow on clinical outcome in low-risk patients with ST-elevation myocardial infarction: results from the ATLANTIC study (2018) (1)
Impact of left atrial appendage closure on left atrial hemodynamics (2021) (1)
Influence of Culprit Lesion Intervention on Outcomes in Infarct-Related Cardiogenic Shock With Cardiac Arrest. (2023) (1)
RELATION OF STROKE AND BLEEDING RISK PROFILES TO EFFICACY AND SAFETY OF DABIGATRAN IN ATRIAL FIBRILLATION AFTER PCI: AN ANCILLARY ANALYSIS FROM THE RE-DUAL PCI TRIAL (2018) (1)
Reply: Has Prasugrel Been Compared Correctly With Clopidogrel in Non-ST-Segment Elevation Acute Coronary Syndrome? (2015) (1)
Cangrelor: Fixing Life or Just a Leak? (2016) (1)
P4207The natural history of premature coronary artery disease over 20 years: the AFIJI registry (2018) (1)
ASSOCIATION OF HUB AND SPOKE PRACTICE PATTERNS WITH CORONARY INTERVENTION AND OUTCOMES IN NON ST ELEVATION ACUTE CORONARY SYNDROMES (NSTE ACS): INSIGHTS FROM THE EARLY GLYCOPROTEIN IIB/IIIA INHIBITION IN NSTE ACS (EARLY-ACS) TRIAL (2011) (1)
Abstract 13993: Impact of Prasugrel Pretreatment and Timing of Coronary Artery Bypass Grafting on Clinical Outcomes of Patients With Non-ST-Segment Elevation Myocardial Infarction: From the Accoast Study (2014) (1)
2013 ESC clinical practice guidelines on diagnosis and treatment of stable ischemic heart disease (2014) (1)
Quelle dose d’aspirine dans le syndrome coronaire aigu ? (2007) (1)
Images in cardiovascular medicine. Heart injury from firearm. (1996) (1)
Transradial Percutaneous Coronary Intervention for Major Reduction of Bleeding Complications (2012) (1)
Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial. (2013) (1)
Les inhibiteurs de la GPIIb\IIIa à la phase aiguë de l‘infarctus du myocarde (2004) (1)
Glycoprotein IIb/IIIa receptors and primary stenting in acute myocardial infarction (2001) (1)
La maladie coronaire du sujet jeune (2008) (1)
Prise en charge de l’infarctus du myocarde en 2012 (2012) (1)
Cardiovascular findings in arterial tortuosity syndrome (2015) (1)
Abstract 19642: Consistent Benefit of Ticagrelor Both Early and Late in Patients With Prior MI in PEGASUS-TIMI 54 (2015) (1)
[What do we know about the cardiovascular toxicity of the NSAIDs?]. (2006) (1)
Le diabète influence-t-il les choix thérapeutiques médicamenteux chez le patient coronarien ? (2004) (1)
Improved clinical outcomes with abciximab therapy in acute myocardial infarction: A systematic overview of randomized clinical trials (2003) (1)
Pretreatment with P2Y12 inhibitors in non-ST-segment elevation acute coronary syndrome: Time to revise the guidelines? (2014) (1)
Moving Toward Eradication of Stent Thrombosis. (2016) (1)
Évaluation ultrasonore de la valve mitrale lors de la valvuloplastie mitrale percutanée (1998) (1)
lopidogrel 150 mg / day to Overcome Low esponsiveness in Patients Undergoing Elective ercutaneous Coronary Intervention esults From the VASP-02 ( Vasodilator-Stimulated Phosphoprotein-02 ) andomized Study (2008) (1)
Lack of correlation between ACT levels and outcomes in patients undergoing elective percutaneous coronary intervention with unfractionated heparin: the STEEPLE trial (2006) (1)
3911Impact of CETP inhibition with evacetrapib in patients with diabetes mellitus: results from ACCELERATE (2017) (1)
Safety and efficacy of subcutaneous enoxaparin in early invasive strategy of unstable angina (2003) (1)
Altered fibrin clot structure/function and FXIII Leu34 genetic variant in patients with premature coronary artery disease (2012) (1)
Despite a mixed reactivity to antiplatelet agents, obese patients have no benefit of platelet function monitoring: insight from the ARCTIC study (2013) (1)
Effects of ON-Hours Versus OFF-Hours Admission on Outcome in Patients With Myocardial Infarction and Cardiogenic Shock (2020) (1)
Tuesday, 28 August 2012 (2012) (1)
IIb/IIIa inhibitors in acute myocardial infarction. (1999) (1)
Left Atrial Appendage Closure: Only a Question of Bleeding! (2019) (1)
The arranged marriage of cangrelor and bivalirudin. (2015) (1)
Antiplatelets and Anticoagulation in the Setting of Acute Heart Failure Syndrome (2008) (1)
Abstract 15899: Pro-Adrenomedullin (mr-proadm) Can Predict Short and Long Term Mortality in Stemi Patients (2011) (1)
Nouveaux antiagrégants plaquettaires (2008) (0)
H034 Rôle pronostique à long terme de l’aldostérone plasmatique dans l’angioplastie coronaire non urgente (2009) (0)
Anomalies de la glycorégulation dans les syndromes coronaires aigus : prévalence, impact pronostique et méthodes de dépistage (2005) (0)
Antithrombotiques et anticoagulants dans la maladie coronaire (1999) (0)
Les héparines de bas poids moléculaire dans l’angor instable et l’infarctus du myocarde sans onde Q : données nouvelles et controverses (1999) (0)
Traitement du thrombus dans les syndromes coronaires aigus en salle de cardiologie interventionnelle (2007) (0)
Syndrome coronaire aigu Sans?ST (2002) (0)
Antiagrégant et anticoagulant en association dans la maladie coronaire chronique : rationnel d’une double voie d’inhibition (2019) (0)
Le séquençage du gène de la transthyrétine est un examen rentable et non invasif qui peut être demandé en première intention devant une cardiopathie présumée amyloïde sans argument biologique sérique pour une amylose AL ou AA (2015) (0)
Choc cardiogénique et arrêt cardiaque : fin du scepticisme thérapeutique ? (2003) (0)
Les nouveaux médicaments antiplaquettaires (1998) (0)
Examens cardiaques paracliniques (1992) (0)
Fibrinolyse et double antiagrégation (2008) (0)
Angiographie quantitative et resténose coronaire (1994) (0)
Arrêt des antiagrégants plaquettaires : un nouveau facteur de risque de syndrome coronaire aigu ? (2005) (0)
Hémoglobinurie paroxystique nocturne et thrombose coronaire aiguë (2004) (0)
Resténose coronaire : le cardiologue face aux problèmes de définitions (1995) (0)
Pronostic des insuffisants rénaux présentant un syndrome coronaire aigu (2005) (0)
Antiagrégants plaquettaires et endoscopie digestive (2006) (0)
Inhibiteurs de la glycoprotéine IIbIIIa (2009) (0)
Actions vasculaires des prostaglandines : athérome, vasoconstriction et ischémie (1992) (0)
Cas cliniques de l'article : Syndromes coronaires aigus avec et sans sus-décalage du segment ST (2017) (0)
Intérêts et limites des classifications de risque en angioplastie coronair (1996) (0)
Le prétraitement dans le syndrome coronaire aigu (2014) (0)
Syndromes coronaires aigus : nouvelle approche (2005) (0)
Autoévaluations de l'article : Syndromes coronaires aigus avec et sans sus-décalage du segment ST (2017) (0)
Les atteintes coronariennes lupiques : une étude cas-témoins sur données angiographiques (2017) (0)
Iconographies supplémentaires de l'article : Syndromes coronaires aigus avec et sans sus-décalage du segment ST (2017) (0)
L'épopée du clopidogrel : que reste-t-il à faire ? (2005) (0)
Effets cardiovasculaires des produits de contraste iodés (1991) (0)
L’artériopathie oblitérante des membres inférieurs est une maladie grave : la confirmation du registre REACH France (2007) (0)
De GISSI-2 à ASIS-1 : la thrombine est-elle une bonne cible dans le traitement de l’infarctus du myocarde ? (1996) (0)
La peur de perdre (2001) (0)
Main air pollutants and out-of-hospital cardiac arrest: A systematic review and meta-analysis (2023) (0)
Wednesday, 29 August 2012 (2012) (0)
Comparison of the safety and efficacy of antithrombotic regimens following TAVR in patients without having an indication for chronic oral anticoagulation (2022) (0)
Cognitive impairment and dementia in atrial fibrillation: a meta- analysis (0)
Eplerenone Post Myocardial Infarction Plus Standard Treatment May Prevent Adverse Cardiovascular Outcomes (2013) (0)
A prospective cardiometabolism ApPRoach of mechanisms of coronary plaque rupture to apprehend patients at risk of recurrent events — The APPROACH registry (2018) (0)
Comparison of risk prediction models in infarct-related cardiogenic shock (2021) (0)
Exercise-induced ventricular arrythmia in asymptomatic patients with Mitral Valve Prolapse (2022) (0)
ATOLL Study Shows Intravenous Enoxaparin is Associated with Better Ischemic Outcomes in Primary PCI for STEMI than UHF (2010) (0)
P1725Current spectrum and 1-year mortality of cardiogenic shock in Europe. Results of the CULPRIT-SHOCK randomized clinical trial and registry (2019) (0)
BEST POSTERS IN NUCLEAR CARDIOLOGY (0)
280 Prospective international observational registry of patient at risk for atherothrombotic events: the French data (2010) (0)
Reduced proximal aortic distensibility is related to recurrent ischemic events in premature coronary artery disease (2020) (0)
Prasugrel Superior to Clopidogrel in Patients with ST-Elevation Myocardial Infarction (2008) (0)
Direct stenting versus stenting after predilatation in STEMI patients with high thrombus burden: a subanalysis from the randomized COMPARE CRUSH trial (2022) (0)
Have the ESC guidelines improved the identification and prevention of individuals at risk of premature myocardial infarction? (2022) (0)
Exercise-induced ventricular arrythmia in patients with mitral valve prolapse (2023) (0)
ADP-receptor antagonists in patients with acute myocardial infarction complicated by cardiogenic shock: a pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis (2021) (0)
e n g l a n d j o u r n a l of m e d i c i n e PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock (2017) (0)
Results from the nationwide French registry ODIACOR. A call to optimize risk factors control and reach the targets in coronary diabetic patients (2022) (0)
Saturday, 17 July 2010 (2010) (0)
Abstract 3297: The Impact of Renal Dysfunction on Bleeding and Outcome in ST-Elevation MI: Results of the ExTRACT-TIMI25 Study (2006) (0)
040 - Non ST-elevation myocardial infarction with a normal coronary angiogram in women: is it serious? (2011) (0)
Prolonged DAPT is Unnecessary Post-Stenting in Patients Who are Event-Free at 1 Year (2013) (0)
P1069Should we care about post-procedural troponin in elective coronary stenting? (2017) (0)
Ticagrelor or prasugrel in STEMI patients: a pharmacodynamic evaluation (2013) (0)
94. Pharmacological remodeling of platelet-rich clots architecture by ABCIXIMAB (C-7E3) may explain the mechanism of its curative antithrombotic effect (1998) (0)
TCT-24 Long-Term Efficacy of Pre-Hospital Crushed Versus Integral Prasugrel in Patients Presenting With ST-Segment Elevation Myocardial Infarction: One-Year Results From the Randomized COMPARE CRUSH Trial (2021) (0)
Oral antiplatelet agent interruption: a new risk marker of acute coronary syndrome? (2005) (0)
Edinburgh Research Explorer Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (2017) (0)
The respective values of anti-GPIIb/IIIa agents and low molecular weight heparin in the treatment of unstable angina (1999) (0)
Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients (2015) (0)
One year follow up results of the FINESSE trial of facilitated PCI (2008) (0)
Aspirin dose and cardiovascular disease prevention. Authors' reply (2007) (0)
Ischemia in Patients With Angina Pectoris (2005) (0)
[Cellular mechanisms of pulmonary vasoconstriction in an experimental model of protamine reversal of heparin]. (1990) (0)
Superior efficacy of low molecular weight heparin versus unfractionated heparin in acute coronary syndromes without ST elevation (2003) (0)
P2245Impact and predictive factors of bleeding complications in elderly patients admitted for an acute coronary syndrome: insights from the ANTARCTIC trial (2018) (0)
Adverse heparin-protamine neutralization interactions and the lung (1991) (0)
Major ESC Clinical Practice Guidelines Issued (2013) (0)
Abstract 3805: The Use of COX-2 Inhibitors and the Risk of Myocardial Infarction in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) Trial (2006) (0)
Transcatheter Patent Foramen Ovale Closure in Patients With Transient Ischemic Attack. (2022) (0)
[What do we know about the cardiovascular toxicity of the NSAIDs?]. (2006) (0)
Acute coronary syndromes Contemporary registries on P 2 Y 12 inhibitors in patients with acute coronary syndromes in Europe : overview and methodological considerations (2015) (0)
TCT-111 Efficacy and safety of glycoprotein IIb/IIIa inhibitors on top of a potent P2Y12 inhibitor in STEMI: A pre-specified sub-analysis of the ATLANTIC trial (2018) (0)
[Does diabetes affect the choice of pharmaceutical treatment in coronary artery disease?]. (2004) (0)
Transcatheter Closure of Patent Foramen Ovale in Patients With Peripheral (Noncerebrovascular) Embolism. (2022) (0)
[Medical treatment of acute coronary syndrome without ST-segment elevation]. (2003) (0)
2050Impact on clinical outcome of on-treatment platelet reactivity according to concordant platelet function tests: the multi-test platelet function study (2017) (0)
TCT-164 Assessment of the efficacy of ex vivo platelet transfusion in the restoration of platelet function in acute coronary syndrome and PCI presenters treated with clopidogrel, prasugrel or ticagrelor - The APTITUDE study (2013) (0)
Atherothrombotic coronary disease in young patients : an update (2000) (0)
Background—Individualizing antiplatelet therapy after platelet function testing did not improve outcome after coronary stenting in the Assessment by a Double Randomization of a Conventional Antiplatelet Strategy Versus a Monitoring- Guided Strategy for Drug-Eluting Stent Implantation and of Treatmen (2014) (0)
160. High fibrinogen level is associated with coronary atherosclerosis in cardiac transplant patients (1996) (0)
Pretreatment before PCI with Prasugrel Does Not Reduce Ischemic Events in Patients with NSTE-ACS (2013) (0)
[Focus on anticoagulants]. (1991) (0)
205 Predictors of outcome in very high-risk patients undergoing transaortic valve replacement (2012) (0)
Abstract 15055: Vasp Measurement by a New Elisa Technique: A Reliable Method, Easier and Faster Than Flow Cytometry (2012) (0)
No Benefit of platelet function monitoring in diabetic patients despite a higher on-treatment platelet reactivity: insight from the ARCTIC study (2013) (0)
009 Still a place for DES for PCI of short (≤15 mm) coronary lesions in large (≥3.0 mm) vessels in patients with diabetes mellitus? (2011) (0)
Hemodynamic effects of intravenously administered quinacainol evaluation in patients with normal left ventricular function (1990) (0)
[Coronary thrombosis: Physiopathology and treatment in the era of tailored medicine]. (2017) (0)
P2771What is the current need for PCI and extra-corporal-life-support (ECLS) in patients referred to a tertiary center for out-of-hospital-cardiac-arrest? (2017) (0)
Low-molecular-weight heparin alone and with IIb/IIIa inhibitors in patients with renal failure and non-ST elevation acute coronary syndromes: Insights from the global registry of acute coronary events (2003) (0)
Antiplatelet Therapy in Acute Coronary Syndrome (ACS) and PCI: Practical Strategies to Improve Outcomes (2010) (0)
[Low molecular weight heparin in unstable angina and myocardial infarction without Q wave]. (1999) (0)
Therapeutic Ultrasound Peripheral and Coronary Angioplasty Using the Angioson System (1996) (0)
Abstract 17991: High Doses Of Clopidogrel To Overcome Genetic Resistance: The Randomized Cross-over Clovis-2 Study (2010) (0)
βeta Blocker Interruption after Uncomplicated Myocardial Infarction: Rationale and Design of the randomized ABYSS trial. (2023) (0)
[Present and future developments of antithrombotic agents]. (2006) (0)
329 Is there an optimal time for catheterization in NSTE-ACS patients with renal failure? Insights from the ABOARD Study (ABOARD: Angioplasty to Blunt the rise Of troponin in Acute coronary syndrome Ran) (2011) (0)
Reply: Oral Anticoagulant Dose Adjustment After TAVR: The Role of Closure Time With Adenosine Diphosphate. (2022) (0)
5916Platelet function testing predicts bleeding complications in elderly patients admitted for an acute coronary syndrome: insights from the ANTARCTIC trial (2018) (0)
Antithrombin Drugs: LMWH, Unfractionated Heparin, Direct Thrombin Inhibitors (2009) (0)
Abstract 16391: The Impact of Smoking on Clinical Outcomes and the Role of Double-Dose versus Standard-Dose Clopidogrel Among Individuals With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention - Insights From the CURRENT-OASIS 7 Trial (2016) (0)
Clinical practice guidelines of the ESC on myocardial revascularization, 2014 (2015) (0)
Can a stable coronary artery disease patient be at high ischaemic risk for scheduled non-cardiac surgery? (2018) (0)
Reply: Atrial Fibrillation Post-PFO Closure. (2022) (0)
THU0379 Coronary artery disease in sle: a case-controlled angiographic study (2018) (0)
[Role of glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes]. (2003) (0)
SAFETY AND EFFICACY OF ADJUSTED-DOSE EPTIFIBATIDE IN PATIENTS WITH ACUTE CORONARY SYNDROMES AND REDUCED RENAL FUNCTION (2010) (0)
did achieve a borderline significantly higher incidence of ischemic strokes compared with 160 mg of aspirin alone in this trial, no difference was found compared with the sec- ond larger arm of 80 mg of aspirin plus warfarin. Because (2017) (0)
Reply: Mineralocorticoid Receptor Antagonism in Acute Myocardial Infarction: Who Benefits? (2016) (0)
Very low-dose aspirin in patients with stable angina (1993) (0)
Oral Antiplatelet Therapy (2010) (0)
P4809Possible benefits of left atrial appendage closure for stroke prevention in patients with atrial fibrillation in real life setting (2018) (0)
Sex-related differences in STEMI patients treated by primary PCI (2013) (0)
062 One year clinical outcomes after percutaneous coronary intervention with drug-eluting stent in patients with chronic renal failure (2010) (0)
Reply: Subclassification of CYP2C19 Genotyping for Better-Adjusted Thienopyridine Treatment. (2020) (0)
P3733Long term follow-up after percutaneous closure of patent foramen ovale for secondary prevention of stroke (2019) (0)
Impact of heterozygous familial hypercholesterolemia on mortality in ST-segment elevation Myocardial Infarction patients (2018) (0)
Sheath management in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial (2006) (0)
Iconographies supplémentaires de l'article : 027 - Impact of Gamma’ Fibrinogen in Premature Acute Coronary Syndrome: a cardiovascular risk factor? (2010) (0)
Abstract 3998: Patients on Chronic Warfarin Therapy Who Present With an Acute Coronary Syndrome are High Risk and Receive Delayed and Inadequate Treatment (2006) (0)
Data for: Copeptin as a Prognostic Biomarker in Acute Myocardial Infarction. (2018) (0)
Iconographies supplémentaires de l'article : Pretreatment with P2Y 12 inhibitors in non–ST-segment elevation acute coronary syndrome: Time to revise the guidelines? (2014) (0)
Antithrombotic treatment in chronic coronary artery disease (1999) (0)
021 2C19*2 genetic variant: a new risk factor for stent thrombosis, myocardial infarction and cardiovascular mortality (2010) (0)
Sex-stratified differences in early antithrombotic treatment response in patients presenting with ST-segment elevation myocardial infarction. (2022) (0)
EVALUATION OF RESIDUAL PLATELET REACTIVITY AFTER ST ELEVATION MYOCARDIAL INFARCTION IN HUMAN IMMUNODEFICIENCY VIRUS, THE EVRE2ST-HIV STUDY (2015) (0)
High on-treatment platelet reactivity, a marker of bleeding risk? An analysis of the ARCTIC study (2013) (0)
Blockbuster interactions: are they bad for the patient? (2012) (0)
The false illusion of coronary thrombus device-management. (2018) (0)
Pharmacodynamic response to clopidogrel and outcomes in the ARCTIC randomized trial (2013) (0)
CRT-100.35 Predictors of Early Myocardial Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPARE CRUSH Trial (2022) (0)
in Patients Undergoing Percutaneous Coronary Intervention (2013) (0)
Abstract 986: Hematomas of at Least 5 Cm and Outcomes in Patients Undergoing Elective Percutaneous Coronary Intervention: Insights From The STEEPLE Trial (2008) (0)
1213Post-TAVR antithrombotic treatment and one-year survival: insights from the FRANCE TAVI registry (2018) (0)
Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study (2015) (0)
[Vascular action of prostaglandins: atheroma, vasoconstriction and ischemia]. (1992) (0)
[Coronary restenosis: the cardiologist facing problems of definitions]. (1995) (0)
Cost-effectiveness of 82-Rubidium PET myocardial perfusion imaging for the diagnosis of myocardial ischemia depending on the prevalence of coronary artery disease (2023) (0)
The relative expansion of the left atrium over the left ventricle to detect early-stage heart failure with preserved ejection fraction (2019) (0)
P5400Professional status and long-term prognosis of premature coronary artery disease: the AFIJI registry (2018) (0)
0495 : Prediction and prognostic values of biomarkers of contrast induced acute kidney injury in ST-segment elevetaion myocardial infarction treated by primary percutaneous coronary intervention (2016) (0)
TCT-23 Influence of the Circadian Clock on the Pharmacodynamic Effect of Prasugrel in Patients Presenting With ST-Segment Elevation Myocardial Infarction—A COMPARE CRUSH Subanalysis (2022) (0)
[Management coronary syndrome in the acute phase]. (2007) (0)
Abstract 12800: Lesion Location and Outcome in Patients With Multi-Vessel Disease and Acute Myocardial Infarction-Related Cardiogenic Shock, a Sub-Analysis of the Culprit-Shock Trial (2019) (0)
Intervention Timing and Acute Coronary Syndromes—Reply (2010) (0)
Optimal antiplatelet and anticoagulation therapy, prevention and management of thrombotic complications (2006) (0)
RELATIONSHIP BETWEEN BLEEDING AND MORTALITY IN PATIENTS ON DUAL ANTIPLATELET THERAPY VS ASPIRIN ALONE: RESULTS FROM THE CHARISMA TRIAL (2011) (0)
Abnormal glucose metabolism in acute coronary syndrome. (2005) (0)
INCIDENCE AND PROGNOSIS OF CARDIAC ALLOGRAFT VASCULOPATHY IN HEART TRANSPLANT PATIENTS (2020) (0)
P5737Use of the IMPELLA mechanical support device in patients with acute myocardial infarction complicated by cardiogenic shock - Results of the CULPRIT-SHOCK trial (2019) (0)
Abstract 16988: Transfusion Induces Platelet Activation and Aggregation (2010) (0)
041 Identification of the optimal timing of invasive strategy in acute coronary syndromes: analysis from the ABOARD Study (2011) (0)
High diagnostic performances of 82 Rubidium-PET for the detection of coronary artery disease as compared to 99 Tc-MIBI with CZT gamma cameras in a population of overweighed patients and women (2017) (0)
TCT-138 Clopidogrel Pretreatment in Non ST Elevation Acute Coronary Syndroms: no effect on mortality, decrease in ischemic endpoints at a price of more major bleeding. (2013) (0)
TCT-137 No benefit of Clopidogrel Pretreatment in stable patients undergoing elective PCI (2013) (0)
032 Clinical, angiographic and genetic determinants of early coronary stent thrombosis: The ONASSIST study (2012) (0)
Neutralization ofLowMolecular Weight Heparin byPolybrene Prevents Thromboxane Release andSevere Pulmonary Hypertension inAwakeSheep (2011) (0)
Combination therapy with low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE) (2003) (0)
Abstract 15664: Enoxaparin versus Unfractionated Heparin in Percutaneous Coronary Intervention: a meta-analysis (2011) (0)
ATLANTIC (Administration of Ticagrelor in the cath Lab or in the Ambulance for New sT elevation myocardial Infarction to open the Coronary artery)—Rationale and Design of the 30 Day International, Randomised, Parallel-group, Double-blind, Placebo-controlled Phase IV Study: The Australian Perspective (2012) (0)
[Antithrombotics and interventional cardiology]. (1999) (0)
Abstract 17107: Identification of the Optimal Timing of Invasive Strategy in Acute Coronary Syndromes: Analysis From the Aboard Study (2010) (0)
Genetics of the Response to Antithrombotic Drugs and the Need for Monitoring (2012) (0)
Aspirin Dose and Cardiovascular Disease Prevention—Reply (2007) (0)
Impact of left atrial appendage closure on left atrial hemodynamics: a prospective single center study (2020) (0)
TCT-827 Clopidogrel Pretreatment Effect according to the clinical presentation in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis (2013) (0)
New frontiers of aspirin therapy (2010) (0)
Incidence and delay of atrial tachycardia after patent foramen ovale closure (2020) (0)
Abstract 2396: Predictors and Implications of Q-waves in ST-Elevation Myocardial Infarction: A Contemporary Perspective from the Global Registry of Acute Coronary Events (2007) (0)
Thrombosis and antithrombotic therapy 881 (2015) (0)
031 Enoxaparin Anticoagulation Monitoring in the Catheterization Laboratory Using a New Point-of-Care test (2010) (0)
Abstract 13918: Outcomes and Effect of PCI Strategies in Culprit-Shock Patients With and Without St-Segment Elevation (2019) (0)
Haemodynamic effects of intravenous quinacainol with and without autonomic nervous system blockade. (1991) (0)
Enoxaparin for Acute Coronary Syndromes ? (2016) (0)
Abstract 13168: Sustained Ventricular Tachycardia and Ventricular Fibrillation are Infrequent Events but are Associated with Increased Arrhythmic and All-cause Death Following Non-ST-Segment Elevation Acute Coronary Syndromes (2010) (0)
Beyond ischaemia: is there a place for physiologic and anatomic evaluations of coronary lesions? (2021) (0)
[New antithrombotic agents in coronary disease]. (1997) (0)
TCT-160 Impact of admission during ON vs. OFF hours in unselected ST-Elevation Myocardial Infarction Patients treated with Primary Percutaneous Coronary Intervention. (2016) (0)
[What dose of aspirin should be prescribed in patients with coronary disease?]. (1995) (0)
[Sarcoma of the heart. Apropos of 2 cases]. (1985) (0)
037 - The relative contribution of the CYP2C19*2 polymorphism in the low responsiveness to clopidogrel in the VASP-02 study (2010) (0)
Anti-xa activity and outcomes in patients undergoing elective percutaneous coronary intervention with intravenous enoxaparin: The STEEPLE trial (2006) (0)
Does severe renal insufficiency increase the risk of bleeding after administration of low-molecular-weight heparin? (2006) (0)
P3855Incidence, risk factors and impact of readmission for heart failure after successful transcatheter aortic valve replacement (2019) (0)
Implication of the new definition of pulmonary hypertension in patients evaluated for heart transplantation. (2023) (0)
1061-85 Trends in the use of effective cardiac medications in patients with acute myocardial infarction: The GRACE experience (2004) (0)
Abstract 15857: High-on Thienopyridine Platelet Reactivity in Elderly Coronary Patients (2011) (0)
[Use of abciximab during coronary angioplasty]. (1997) (0)
Reply: Not All NSTEMIs Are Created Equal. (2015) (0)
Intravenous enoxaparin anticoagulation in percutaneous left atrial cardiac procedures (2018) (0)
[Treatment of intracoronary thrombus in the catheterisation laboratory in acute coronary syndrome patients]. (2007) (0)
Abstract 3134: Aldosterone A Major Determinant Of Long Term Mortality in Elective PCI (2007) (0)
Abstract 15369: Impact of Switching Prasugrel to Clopidogrel on Platelet Inhibition and Clinical Outcomes (2012) (0)
Percutaneous left atrial appendage transcatheter occlusion (PLAATO (TM)) to prevent strokes in patients with atrial fibrillation (AF) - Interim Results of the European Registry Trial (2005) (0)
P2708Impact of heterozygous familial hypercholesterolemia on mortality in ST-segment elevation myocardial infarction patients (2018) (0)
Inhibición de las glucoproteínas IIb/IIIa plaquetarias junto con aplicación de stents coronarios en el infarto agudo de miocardio (2001) (0)
Abstract 15812: Aldosterone Predicts Long-term Secondary Outcome in Patients With Stable Coronary Artery Disease: Results from the SMART prospective cohort study (2010) (0)
201Left atrial appendage closure for stroke prevention in patients with atrial fibrillation: the difficult task of estimating the possible benefit in real life setting (2018) (0)
Intervention Timing and Acute Coronary Syndromes. Authors' reply (2010) (0)
Abstract 4039: Continuous Positive Airway Pressure From Out-of-hospital Setting To Cardiac Intensive Care Unit In Acute Heart Failure: A Multicenter Randomized Study (2008) (0)
P6454Antithrombotic therapy and cardiovascular events in patients with left ventricular thrombus (2019) (0)
Indirect Transfer to Catheterization Laboratory for ST Elevation Myocardial Infarction Is Associated With Mortality Independent of System Delays: Insights From the France-PCI Registry (2022) (0)
A meta-analysis of randomized trials comparing percutaneous closure of patent foramen ovale to medical therapy (2013) (0)
Summary of recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction. (2004) (0)
Poor Outcomes in Chronic Kidney Disease (CKD) With and Without Reperfusion After ST Elevation/Left Bundle Branch Block (STE/LBBB) (2007) (0)
The hazards of approximations and extrapolations: Insights from the ATLANTIC study (2015) (0)
059 Impact of immediate coronary angiography and new reanimation techniques in cardiac arrest patients (2011) (0)
Impact of the Antiplatelet Strategy Following Patent Foramen Ovale Percutaneous Closure. (2023) (0)
MINERALOCORTICOID RECEPTOR ANTAGONISTS IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED TRIALS (2017) (0)
P1722Platelet function monitoring for the prediction of clinical outcomes: a pooled analysis of the randomized ARCTIC and ANTARCTIC trials (2018) (0)
TCT-46 Pre-Hospital Crushed Versus Integral Prasugrel Loading Dose in Patients Presenting With Anterior ST-Segment Elevation Myocardial Infarction—A COMPARE CRUSH Subanalysis (2022) (0)
ex-related differences after contemporary rimary percutaneous coronary ntervention for ST-segment elevation yocardial infarction nfluence du genre sur le pronostic après angioplastie primaire (2015) (0)
Haemodynamic Effects of Intravenous Urapidil in Patients with Advanced Left Ventricular Failure (2012) (0)
032: Thirty months outcomes after PCI of unprotected left main coronary artery according to the SYNTAX score (2013) (0)
P6233Intima-Media thickness to better risk-stratify patients with premature coronary artery disease: an analysis from the AFUI registry (2018) (0)
Coronary Heart Disease Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes (2011) (0)
TCT-748 Double The Dose Of Clopidogrel Or Switch To Prasugrel To Antagonize Proton Pump Inhibitor Interaction (2012) (0)
Abstract 3009: Major Subgroup Analyses from the FINESSE Trial: Evaluation of Abciximab + Half -Dose Reteplase, Abciximab Alone, or Placebo for Facilitation of Primary PCI for ST Segment Elevation MI (2007) (0)
Rationale and design of the RIGHT trial: A multicenter, randomized, double-blind, placebo-controlled trial of anticoagulation prolongation versus no anticoagulation after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. (2020) (0)
Corrigendum: new insights for low dosing with the new P2Y₁₂ inhibitors – lesson from the East. (2014) (0)
Left ventricular dyssynchrony and dynamic functional mitral regurgitation : relationship or association ? (2006) (0)
Universal reperfusion therapy: when good is never good enough. (2009) (0)
Education Program Fails to Improve Adherence to Apixaban: The AEGEAN Study (2015) (0)
Iconographies supplémentaires de l'article : 059 - Impact of immediate coronary angiography and new reanimation techniques in cardiac arrest patients. (2011) (0)
W1924 Prevalence and Clinical Impact of Upper Gastrointestinal Symptoms in Patients Treated with Low-Dose Aspirin (2008) (0)
Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study (2014) (0)
ANTARCTIC: platelet function testing to adjust therapy – Authors' reply (2017) (0)
009 Red Blood Cell Transfusion Increase Platelet Aggregation: a potential mechanism for increased mortality in transfused patients (2010) (0)
Speed to Stop Events) Trial From the FINESSE (Facilitated Intervention With Enhanced Reperfusion 1-Year Survival in a Randomized Trial of Facilitated Reperfusion: Results (2011) (0)
Thrombosis after implantation of drug-eluting stents. Authors' reply (2006) (0)
IT FITS! (Intelligence Transfer: From Images to Solutions) Intracoronary Stenting of a Myocardial Bridge (1999) (0)
011 Does the type of stent matter in ‘real life’ PCI? (2012) (0)
1025-66 Biological markers of the restenosis (2004) (0)
Antithrombotic therapy and cardiovascular events in patients with left ventricular thrombus (2020) (0)
Quel traitement adjuvant antithrombotique aux thrombolytiques en phase aiguë d'infarctus du myocarde ? : Infarctus du myocarde (1998) (0)
Reply: Do not miss the elephant in the room: look at the red blood cells. (2014) (0)
Abstract 2146: Drug Eluting Stents (DES) in AMI patients. Insights from FINESSE (2007) (0)
Peri-procedural thrombin generation predicts ischemic complications in primary percutaneous coronary intervention of ST-elevation myocardial infarction: a substudy of the ATOLL trial (2013) (0)
Clopidogrel: still king of the ring for elective percutaneous coronary intervention! (2023) (0)
Abstract 3732: The Influence of Aspirin Dose With or Without Clopidogrel on Efficacy and Safety in the CHARISMA Trial (2006) (0)
[Indium III monoclonal antimyosin antibody scintigraphy for the detection of chronic myocardial infarction apart from the acute phase]. (1995) (0)
P999Major adverse events with percutaneous left atrial appendage closure in patients with atrial fibrillation in real life setting (2019) (0)
026 Pro-adrenomedullin (MR-proADM) can predict short and long term mortality in STEMI patients (2012) (0)
[Anti-thrombotic therapy of acute coronary syndromes without ST elevation]. (2005) (0)
Reply: The Residual SYNTAX Score: A Useful Tool to Predict Outcomes in Cardiogenic Shock. (2021) (0)
027 Impact of Gamma’ Fibrinogen in Premature Acute Coronary Syndrome: a cardiovascular risk factor? (2010) (0)
Assessment of early administration of abciximab in acute ST-segment elevation myocardial infarction in the emergency department (2005) (0)
038 Major bleeding still predicts death with a radial invasive strategy in NSTE-ACS: an analysis from theABOARD Study (2011) (0)
The (cid:1) C domains of ﬁbrinogen affect the structure of the ﬁbrin clot, its physical properties, and its susceptibility to ﬁbrinolysis (2005) (0)
Pharmacodynamic Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: A Prespecified Subanalysis of The COMPARE CRUSH Trial (2021) (0)
The fear of loosing (2001) (0)
INTERACTION BETWEEN MORPHINE AND TICAGRELOR IN THE ATLANTIC STUDY (2016) (0)
Cardiac diagnostic techniques in dialysis and renal transplant patients (2005) (0)
Abstract 19040: Exome Sequencing of Extreme Phenotypes Identifies B4GALT2 as a Determinant of Clopidogrel Response Variability (2014) (0)
050 Copeptin to improve diagnosis of acute STEMI (2012) (0)
Reply: Should Postprocedure Anticoagulation Be Routinely Needed in Acute STEMI Patients Undergoing Primary PCI? (2022) (0)
Reply: Lights and Shadows of Antiplatelet Therapy in Primary Percutaneous Coronary Intervention. (2015) (0)
Prosthesis choice for surgical treatment of left-sided native valve infective endocarditis: Determinants and impact on outcomes (2021) (0)
Real life versus score-predicted mortality in patients presented to the Heart Team (2017) (0)
Is Pretreatment With P2Y 12 Inhibitors in Non–ST-Segment–Elevation Acute Coronary Syndrome Clinically Justified? Pretreatment with P2Y 12 Inhibitors in Non–ST-Segment– Elevation Acute Coronary Syndrome: An Outdated and Harmful Strategy C ONTrOvErSIES IN C ArDIOvASCULAr M EDICINE (2014) (0)
TCT-272 Influence of Activated Clotting Time on Early Myocardial Reperfusion in Patients With ST-Segment Elevation Myocardial Infarction: Results From the COMPARE CRUSH Trial (2021) (0)
[Non-ST acute coronary syndromes]. (2002) (0)
004 Contrast induced nephropathy after primary PCI for STEMI: Usefulness of a new definition (2012) (0)
How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. (2021) (0)
326 Long-term Outcome after Bare-Metal or Drug-Eluting Stenting for Allograft Coronary Artery Disease (2010) (0)
Abstract 13657: The REG1 Anticoagulation System Allows for Early Arterial Sheath Removal After Cardiac Catheterization Without Increases in Time to Hemostasis or Bleeding Complications: An Analysis From the RADAR Clinical Trial. (2011) (0)
005 - ST-elevation myocardial infarction admission during "ON-" versus "OFF-" hours: is there an impact on outcome for primary PCI? (2011) (0)
TCT-291 Correlation Between Reduced Infarct-Related Artery Patency on Initial Angiography and Post-PCI Reperfusion TIMI Flow in STEMI Patients—A COMPARE CRUSH Subanalysis (2022) (0)
Left atrial appendage occlusion to prevent stroke in suboptimal warfarin candidates: European Multicenter registry trial (2005) (0)
Low-molecular-weight heparin (2018) (0)
Dual antiplatelet treatment after stenting – Authors' reply (2015) (0)
[Management of ST-elevation myocardial infarction in 2012]. (2012) (0)
Stenting and glycoprotein IIb/IIIa inhibition in angioplasty for acute myocardial infarction in the global registry of acute coronary events (GRACE) (2001) (0)
060 Resistance to antiplatelet therapy in the elderly, a real concern. Results of the senior platelet study (2011) (0)
Abstract 3073: Development and Validation of a Bleeding Risk Model for Major Bleeding in Patients Undergoing Elective Percutaneous Coronary Intervention: the STEEPLE Trial (2006) (0)
Percutaneous left atrial appendage occlusion (PLAATO) for stroke prevention: Experience with 180 patients (2006) (0)
Association of 2B3A inhibition with new antiplatelet regimens in the setting of acute coronary syndromes: a meta-analysis of randomized controlled trials (2013) (0)
SYNERGY- EVEROLIMUS ELUTING STENT WITH A BIOABSORBABLE POLYMER IN ST ELEVATION MYOCARDIAL INFARCTION- CLEAR SYNERGY OASIS-9 TRIAL (2022) (0)
004 Predicting early and late mortality in patients presenting for STEMI with CHADS2 score (2010) (0)
Impact and predictive factors of bleeding complications in elderly patients admitted for an acute coronary syndrome: Insights from the ANTARCTIC trial (2019) (0)
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease: 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), Association for Acute CardioVascular Care (ACVC) and European Association of Pr (2023) (0)
[Should all cases of aortic valve stenosis be surgically treated?]. (1994) (0)
MYOCARDIAL ISCHEMIA AND INFARCTION EARLY ALDOSTERONE RECEPTOR BLOCKADE AT PRESENTATION FOR ST ELEVATION MYOCARDIAL INFARCTION IMPROVES OUTCOME: A CASE-CONTROL STUDY (2011) (0)
Immediate versus staged complete myocardial revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease: A post hoc analysis of the randomized FLOWER-MI trial. (2022) (0)
Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. 2004. (2009) (0)
Abstract 15734: Contrast Induced Nephropathy after Primary PCI for STEMI: usefulness of a new definition (2011) (0)
Cangrelor (2023) (0)
Statin therapy is associated with lower prevalence of gut microbiota dysbiosis (2020) (0)
TCT-28 Pharmacodynamic Response, Early Reperfusion, and Clinical Outcomes to Pre-Hospital Prasugrel Administration in Diabetic Patients Presenting With STEMI—A COMPARE CRUSH Subanalysis (2022) (0)
Hyperglycemia increases Hospital Mortality in Patients with Acute Coronary Syndromes: Results from the Global Registry of Acute Coronary Events (2004) (0)
[Postinfarction hibernating myocardium]. (1994) (0)
[Aspirin: towards a new consensus]. (2000) (0)
[Remote results of aortic valve replacement with the St. Jude medical prosthesis]. (1988) (0)
Possible role of microvascular dysfunction in the weak association found between stress myocardial blood flow measured with 82 Rubidium-PET and FFR values measured during coronary angiography (2017) (0)
020 Transfer Time is not a major determinant of in-hospital mortality in Primary PCI when performed in a well organized urban network (2010) (0)
034 High doses of clopidogrel to overcome genetic resistance: the randomized cross-over CLOVIS-2 study (2012) (0)
Identifying higher risk patients among the COMPASS-Eligible population: An analysis from the REduction of Atherothrombosis for Continued Health (REACH) Registry (2019) (0)
[Cardiology. Platelet function testing for clinicians]. (2014) (0)
P4629Thrombus aspiration and pre hospital ticagrelor administration in ST-elevation myocardial infarction: findings from the ATLANTIC trial (2017) (0)
Abstract 5493: Genetic or Acquired CYP2C19 Enzyme Deficit is Associated With an Excess of Cardiovascular Risk in Clopidogrel-treated Patients (2009) (0)
Platelet function testing predicts bleeding complications in elderly patients admitted for an acute coronary syndrome: insights from the ANTARCTIC trial (2019) (0)
ATOPAXAR AND ITS EFFECTS ON MARKERS OF PLATELET ACTIVATION AND INFLAMMATION: RESULTS FROM THE LANCELOT PROGRAM (2012) (0)
Indirect thrombin inhibitors: fundamentals and guide to optimal therapy using unfractionated heparin and low-molecular-weight heparins (2008) (0)
Reply: Left Ventricular Thrombus: When Registries Are Not Good Enough! (2020) (0)
519: Correlates of Mortality and Major Events in Heart Transplant Recipients Treated by Coronary Stents for Transplant Vasculopathy (2008) (0)
039 Slow Response to Clopidogrel Predicts Low Response (2010) (0)
Iconography : Can a stable coronary artery disease patient be at high ischaemic risk for scheduled non-cardiac surgery? (2018) (0)
045 New P2Y12 inhibitors versus clopidogrel in primary percutaneous coronary intervention for STEMI: a meta-analysis (2012) (0)
5914De-escalation versus escalation of antiplatelet therapy in elderly ACS patients: insight from the ANTARCTIC trial (2018) (0)
Iconographies supplémentaires de l'article : Sex-related differences after contemporary primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (2015) (0)
[Hemodynamic effects of quinacainol administered via an intravenous route. Study in patients with normal left ventricular function]. (1990) (0)
366 Intravenous aldosterone blockade at presentation improves myo-cardial perfusion after primary PCI for STEMI (2012) (0)
Radial access in patients with acute coronary syndromes without persistent ST segment elevation: metaanalysis,and metaregression (2016) (0)
Prevalence and factors associated with dyspnea in adult patients with Hemoglobin SC disease: a study of 221 cases (2021) (0)
The Enduring Legacy of Failed Revascularization Trials. (2021) (0)
060 Plasma aldosterone levels predict long-term clinical outcome after percutaneous coronary revascularization (2010) (0)
0474: The deleterious cardiovascular impact of renal failure varies according to PCI indication (2015) (0)
More predictable anticoagulation with intravenous enoxaparin than with unfractionated heparin in patients undergoing primary percutaneous coronary intervention: a substudy of the ATOLL trial (2013) (0)
P3423Impact of oral anticoagulation on clinical outcomes and hemodynamic parameters after successful transcatheter aortic valve replacement (2018) (0)
Abstract 17061: Primary Pci Strategy for Non-st Elevation Acute Coronary Syndrome in Elderly Patients (>75y/o): An Analysis of the Aboard Study (2010) (0)
Warfarin-related hemorrhage after valve replacement. (1988) (0)
Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study (2023) (0)
General cardiologyAbstractsImpact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes (2005) (0)
Heart-breaking aspirin interruption. (2017) (0)
Comparison of methods for quantification of myocardial infarct size from delayed enhancement magnetic resonance data (2012) (0)
240 Pre-hospital abciximab initiation in STEMI. MISTRAL: a prospective controlled randomized double blinded trial (2011) (0)
Abstract 6177: Impact of Transfer Time on Mortality of the Urban STEMI Treated with Primary Angioplasty (2008) (0)
ARCTIC: Randomized Trial of Bedside Platelet Function Monitoring (2012) (0)
Direct thrombin inhibitors : clinical experience and results in arterial and venous thrombosis (1999) (0)
International and time trends in the use and characteristics of patients with acute coronary syndromes treated with clopidogrel: the global registry of acute coronary events experience (2005) (0)
Abstract 18830: Increase in Platelet Reactivity After Red Blood Cell Transfusion in Coronary and Non-coronary Patients: Results from the Transfusion-2 Study (2012) (0)
Incidence, risk factors and impact of readmission for heart failure after successful transcatheter aortic valve replacement (2019) (0)
1155Prognostic impact of SYNTAX Score in patients with myocardial infarction with multivessel coronary artery disease and cardiogenic shock: insight from the CULPRIT-SHOCK Trial (2019) (0)
Impact of dual non-responsiveness to aspirin and clopidogrel on clinical outcomes in patients treated with drug-eluting stents in the ARCTIC study (2013) (0)
060 Platelet reactivity and outcome in high-risk ACS patients treated with prasugrel (2012) (0)
Staged PCI for Residual Multi-Vessel Disease Following Primary PCI Is Associated with Low Mortality (2009) (0)
[New medical anticoagulants]. (1999) (0)
GRACE Registry Study (2009) (0)
P3124Predictive value of the residual SYNTAX score following primary PCI in multivessel patients with MI-related cardiogenic shock - a CULPRIT SHOCK sub-analysis (2019) (0)
Evaluation of Residual Platelet Reactivity in Patients Treated with Aspirin and or Clopidogrel: Comparison of Results Obtained On Multiplate®, PFA-100TM and Classical Light Transmission Aggregometry. (2009) (0)
RAS inhibition and COVID-19: more questions than answers? (2021) (0)
Platelet function monitoring for the prediction of clinical outcomes: A pooled analysis of the randomized ARCTIC and ANTARCTIC trials (2019) (0)
017 Aldosterone receptor blockade at presentation for ST elevation myocardial infarction is associated with a reduction in potentially lethal ventricular arhythmia (2011) (0)
Reply: Supraventricular Arrhythmia: The Most Frequent Complication After PFO Closure. (2023) (0)
Serum cholesterol efflux capacity and mortality in patients with acute myocardial infarction (2019) (0)
Indium-111 antimyosin scintigraphy before and after coronary bypass surgery: unexpected preoperative myocardial uptakes. (1997) (0)
023 Impact of time on thrombus composition in STEMI patients treated with Primary PCI (2010) (0)
Prehospital Ticagrelor Reduces Stent Thrombosis in STEMI (2014) (0)
Iconographies supplémentaires de l'article : 060 - Plasma aldosterone levels predict long-term clinical outcome after percutaneous coronary revascularization (2010) (0)
Echocardiography and renin-aldosterone interplay as predictors of death in COVID-19 (2022) (0)
Abstract 2463: The Relationship Between Obesity, Diabetes and Outcomes in Elective Percutaneous Coronary Intervention: Results from the STEEPLE Trial (2006) (0)
First clinical experience with the wearable cardiac rhythm long-term monitoring cardioskin device (2020) (0)
Rebond d'accident coronarien après l'arrêt des traitements préventifs de la maladie athérothrombose coronaire : le point de vue du cardiologue (2004) (0)
Les héparines de bas poids moléculaire dans l’angor instable et l’infarctus sans onde Q (1998) (0)
Intérêt potentiel des héparines de bas poids moléculaire chez les patients porteurs d’une prothèse valvulaire mécanique (1998) (0)
La gestion de l’arrêt des antiagrégants plaquettaires : un véritable enjeu médical (2006) (0)
Mécanismes de la vasoconstriction pulmonaire provoquée par la neutralisation de l'héparine par la protamine (1989) (0)
Traitement Antithrombotique des Syndromes Coronariens aigus sans Sus-décalage de ST (2005) (0)
Les nouveaux antithrombotiques (1997) (0)
Anticoagulants et prothèses valvulaires (1993) (0)
Les nouvelles frontières du choc cardiogénique (2004) (0)
Aldostérone et infarctus du myocarde (2008) (0)
Prise en charge du syndrome coronaire aigu sans élévation du segment ST, nouveautés des recommandations ESC 2020 (2021) (0)
Abciximab en préhospitalier dans le SCA ST+ : registre RIPOSTE (2009) (0)
Pre-hospital treatment with crushed versus integral tablets of prasugrel in patients presenting with ST-Segment Elevation Myocardial Infarction - One-year follow-up results of the COMPARE CRUSH trial: One-year results from the COMPARE CRUSH trial. (2022) (0)
Le prasugrel en pratique : quel patient ? Comment ? Quelle durée ? (2010) (0)
Traitement antiplaquettaire dans les syndromes coronariens aigus (2009) (0)
Infarctus du ventricule droit (1995) (0)
PLAQUETTES ET SYNDROMES CORONAIRES AIGUS: PHYSIOPATHOLOGIE (1998) (0)
Thrombose coronaire : physiopathologie et traitement à l’ère de la médecine personnalisée (2017) (0)
Résistance au clopidogrel, tests génétiques et tests fonctionnels (2012) (0)
ne-year clinical outcomes in patients with chronic enal failure treated by percutaneous coronary ntervention with drug-eluting stent ésultats cliniques à un an de l ’ angioplastie coronaire avec stent actif chez les atients avec insuffisance rénale chronique (2011) (0)
En attendant ASIS-1 : la thrombine est-elle une bonne cible dans le traitement de l'infarctus du myocarde ? (2eme partie) (1995) (0)
Le traitement antithrombotique de la maladie coronaire chronique (1999) (0)
5 après... GISSI-2 : la thrombine est-elle une bonne cible dans le traitement de l'infarctus du myocarde ? I (1995) (0)
Rétrécissement aortique et dysfonction ventriculaire gauche (1995) (0)
Maladie coronaire et atteinte polyartérielle. Discussion (1993) (0)
Angioplastie coronaire par ballonnet : quelles limites pour la technique interventionnelle percutanée de référence ? (1991) (0)
Prise en charge de l’infarctus du myocarde, nouveautés des Recommandation ESC 2017 (2018) (0)
Les inhibiteurs directs de la thrombine : expérience et bilan clinique dans la thrombose artérielle et veineuse (1999) (0)
FAUT-IL CORONAROGRAPHIER TOUS LES ANGORS INSTABLES ? REPONSES A UNE MAUVAISE QUESTION... (1999) (0)
Complications de l'infarctus du myocarde, évolution et pronostic (2016) (0)
Mécanismes cellulaires de la vasoconstriction pulmonaire dans le modèle expérimental de neutralisation de l'héparine par la protamine (1990) (0)
Développements actuels et futurs des antithrombotiques (2006) (0)
Traitement de l'amylose AL par intensification thérapeutique et autogreffe de cellules souches périphériques : expérience monocentrique de 17 observations (2001) (0)
Arbres décisionnels de l'article : Syndromes coronaires aigus avec et sans sus-décalage du segment ST (2017) (0)
Intérêt de la prise en charge précoce des syndromes coronaires aigus par les anti-GPIIb/IIIa (2003) (0)
Sport et coronaires (1989) (0)
Les traitements adjuvants de la thrombolyse (2001) (0)
Le stent, l'abciximab et l'étagère... (1998) (0)
La détection automatique des interfaces ultrasonores pour l'étude de la fonction ventriculaire gauche. Une technique prometteuse en cours de validation (1993) (0)
La polysomnographie très précoce dans les syndromes coronariens aigus est faisable : résultats d’étude pilote (2014) (0)
P20-11 Risque encouru chez les patients présentant une amylose cardiaque et/ou rénale au cours du recueil de cellules souches périphériques (1998) (0)
Mesure de la viscosité sanguine au cours de l'infarctus du myocarde aigu reperfusé (2008) (0)
Nouveaux antithrombotiques en pathologie coronaire (2002) (0)
Myocardite restrictive révélatrice d'une brucellose (1995) (0)
Stents coronaires et anti-agrégants plaquettaires (2007) (0)
LES NOUVEAUX ANTITHROMBOTIQUES DANS LA MALADIE CORONAIRE : ILS N'ONT PAS ENCORE DETRONE L'ASPIRINE (1996) (0)
L’apport respectif des anti-GPIIb/IIIa et des héparines de bas poids moléculaires dans le traitement de l’angor instable (1999) (0)
Arbres décisionnels de l'article : Syndromes coronaires aigus (2010) (0)
Prise en charge de la maladie coronaire chronique : vers de nouvelles recommandations ? (2019) (0)
Monoxyde d’azote et régulation de l’activité plaquettaire (1997) (0)
Rôle des plaquettes et place des antiagrégants plaquettaires (2003) (0)
Effet thrombolytiques des ultrasons: données expérimentales et cliniques (1993) (0)
Traitements des syndromes coronaires aigus avec et sans sus-décalage du segment ST (2016) (0)
Switch d’antiplaquettaires : ACAPULCO (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Gilles Montalescot?

Gilles Montalescot is affiliated with the following schools:

Gilles Montalescot's Academic­Influence.com Rankings

Gilles Montalescot's Degrees

Why Is Gilles Montalescot Influential?

Gilles Montalescot's Published Works

Published Works

What Schools Are Affiliated With Gilles Montalescot?

Gilles Montalescot's AcademicInfluence.com Rankings